Patent Grant
10159415
The present disclosure relates to medical devices, systems, and methods. In particular, the present disclosure relates to methods and systems for managing health and disease such as cardiac diseases including arrhythmia and atrial fibrillation.
Cardiovascular diseases are the leading cause of death in the world. In 2008, 30% of all global death can be attributed to cardiovascular diseases. It is also estimated that by 2030, over 23 million people will die from cardiovascular diseases annually. Cardiovascular diseases are prevalent in the populations of high-income and low-income countries alike.
Arrhythmia is a cardiac condition in which the electrical activity of the heart is irregular or is faster (tachycardia) or slower (bradycardia) than normal. Although many arrhythmias are not life-threatening, some can cause cardiac arrest and even sudden cardiac death. Atrial fibrillation is the most common cardiac arrhythmia. In atrial fibrillation, electrical conduction through the ventricles of heart is irregular and disorganized. While atrial fibrillation may cause no symptoms, it is often associated with palpitations, shortness of breath, fainting, chest, pain or congestive heart failure. Atrial fibrillation is also associated with atrial clot formation, which is associated with clot migration and stroke.
Atrial fibrillation is typically diagnosed by taking an electrocardiogram (ECG) of a subject, which shows a characteristic atrial fibrillation waveform
To treat atrial fibrillation, a patient may take medications to slow heart rate or modify the rhythm of the heart. Patients may also take anticoagulants to prevent atrial clot formation and stroke. Patients may even undergo surgical intervention including cardiac ablation to treat atrial fibrillation.
Often, a patient with arrhythmia or atrial fibrillation is monitored for extended periods of time to manage the disease. For example, a patient may be provided with a Holter monitor or other ambulatory electrocardiography device to continuously monitor a patient's heart rate and rhythm for at least 24 hours.
Current ambulatory electrocardiography devices such as Holter monitors, however, are typically bulky and difficult for subjects to administer without the aid of a medical professional. For example, the use of Holter monitors requires a patient to wear a bulky device on their chest and precisely place a plurality of electrode leads on precise locations on their chest. These requirements can impede the activities of the subject, including their natural movement, bathing, and showering. Once an ECG is generated, the ECG is sent to the patient's physician who may analyze the ECG and provide a diagnosis and other recommendations. Currently, this process often must be performed through hospital administrators and health management organizations and many patients do not receive feedback in an expedient manner.
Disclosed herein are devices, systems, and methods for managing health and disease such as cardiac diseases, including arrhythmia and atrial fibrillation. In particular, a cardiac disease and/or rhythm management system, according to aspects of the present disclosure, allows a user to conveniently document their electrocardiograms (ECG) and other biometric data and receive recommendation(s) and/or goal(s) generated by the system or by a physician in response to the documented data. The cardiac disease and/or rhythm management system can be loaded onto a local computing device of the user, where biometric data can be conveniently entered onto the system while the user may continue to use the local computing device for other purposes. A local computing device may comprise, for example, a computing device worn on the body (e.g. a head-worn computing device such as a Google Glass, a wrist-worn computing device such as a Samsung Galaxy Gear Smart Watch, etc.), a tablet computer (e.g. an Apple iPad, an Apple iPod, a Google Nexus tablet, a Samsung Galaxy Tab, a Microsoft Surface, etc.), a smartphone (e.g. an Apple iPhone, a Google Nexus phone, a Samsung Galaxy phone, etc.)
A portable computing device or an accessory thereof may be configured to continuously measure one or more physiological signals of a user. The heart rate of the user may be continuously measured. The continuously measurement may be made with a wrist or arm band or a patch in communication with the portable computing device. The portable computing device may have loaded onto (e.g. onto a non-transitory computer readable medium of the computing device) and executing thereon (e.g. by a processor of the computing device) an application for one or more of receiving the continuously measured physiological signal(s), analyzing the physiological signal(s), sending the physiological signal(s) to a remote computer for further analysis and storage, and displaying to the user analysis of the physiological signal(s). The heart rate may be measured by one or more electrodes provided on the computing device or accessory, a motion sensor provided on the computing device or accessory, or by imaging and lighting sources provided on the computing device or accessory. In response to the continuous measurement and recordation of the heart rate of the user, parameters such as heart rate (HR), heart rate variability (R-R variability or HRV), and heart rate turbulence (HRT) may be determined. These parameters and further parameters may be analyzed to detect and/or predict one or more of atrial fibrillation, tachycardia, bradycardia, bigeminy, trigeminy, or other cardiac conditions. A quantitative heart health score may also be generated from the determined parameters. One or more of the heart health score, detected heart conditions, or recommended user action items based on the heart health score may be displayed to the user through a display of the portable computing device.
The biometric data may be uploaded onto a remote server where one or more cardiac technicians or cardiac specialists may analyze the biometric data and provide ECG interpretations, diagnoses, recommendations such as lifestyle recommendations, and/or goals such as lifestyle goals for subject. These interpretations, diagnoses, recommendations, and/or goals may be provided to the subject through the cardiac disease and/or rhythm management system on their local computing device. The cardiac disease and/or rhythm management system may also include tools for the subject to track their biometric data and the associated interpretations, diagnoses, recommendations, and/or goals from the cardiac technicians or specialists.
An aspect of the present disclosure includes a dashboard centered around arrhythmia or atrial fibrillation tracking. The dashboard includes a heart score that can be calculated in response to data from the user such as their ECG and other personal information such as age, gender, height, weight, body fat, disease risks, etc. The main driver of this heart score will often be the incidence of the user's atrial fibrillation. Other drivers and influencing factors include the aforementioned personal information. The heart score will be frequently related to output from a machine learning algorithm that combines and weights many if not all of influencing factors.
The dashboard will often display and track many if not all of the influencing factors. Some of these influencing factors may be entered directly by the user or may be input by the use of other mobile health monitoring or sensor devices. The user may also use the dashboard as an atrial fibrillation or arrhythmia management tool to set goals to improve their heart score.
The dashboard may also be accessed by the user's physician (e.g. the physician prescribing the system to the user, another regular physician, or other physician) to allow the physician to view the ECG and biometric data of the user, view the influencing factors of the user, and/or provide additional ECG interpretations, diagnoses, recommendations, and/or goals.
Another aspect of the present disclosure provides a method for managing cardiac health. Biometric data of a user may be received. A cardiac health score may be generated in response to the received biometric data. One or more recommendations or goals for improving the generated cardiac health score may be displayed to the user. The biometric data may comprise one or more of an electrocardiogram (ECG), dietary information, stress level, activity level, gender, height, weight, age, body fat percentage, blood pressure, results from imaging scans, blood chemistry values, or genotype data. The recommendations or goals may be updated in response to the user meeting the displayed recommendations or goals. The user may be alerted if one or more recommendations or goals have not been completed by the user, for example if the user has not completed one or more recommendations or goals for the day.
The analysis applied may be through one or more of the generation of a heart health score or the application of one or more machine learning algorithms. The machine learning algorithms may be trained using population data of heart rate. The population data may be collected from a plurality of the heart rate monitoring enabled portable computing devices or accessories provided to a plurality of users. The training population of users may have been previously identified as either having atrial fibrillation or not having atrial fibrillation prior to the generation of data for continuously measured heart rate. The data may be used to train the machine learning algorithm to extract one or more features from any continuously measured heart rate data and identify atrial fibrillation or other conditions therefrom. After the machine learning algorithm has been trained, the machine learning algorithm may recognize atrial fibrillation from the continuously measured heart rate data of a new user who has not yet been identified as having atrial fibrillation or other heart conditions. One or more of training population data or the trained machine learning algorithm may be provided on a central computing device (e.g. be stored on a non-transitory computer readable medium of a server) which is in communication with the local computing devices of the users and the application executed thereon (e.g. through an Internet or an intranet connection.)
A set of instructions for managing cardiac health may be downloaded from the Internet. These set of instructions may be configured to automatically generate the cardiac health score. The cardiac health score may be generated using a machine learning algorithm. The machine learning algorithm may generate the cardiac health score of the user and/or the recommendations and/or goals in response to biometric data from a plurality of users. The set of instructions may be configured to allow a medical professional to access the received biometric data. The cardiac health score and/or the recommendations and/or goals may be generated by the medical professional.
The set of instructions may be stored on a non-transitory computer readable storage medium of one or more of a body-worn computer, a tablet computer, a smartphone, or other computing device. These set of instructions may be capable of being executed by the computing device. When executed, the set of instructions may cause the computing device to perform any of the methods described herein, including the method for managing cardiac health described above.
Another aspect of the present disclosure provides a system for managing cardiac health. The system may comprise a sensor for recording biometric data of a user and a local computing device receiving the biometric data from the sensor. The local computing device may be configured to display a cardiac health score and one or more recommendations or goals for the user to improve the cardiac health score in response to the received biometric data.
The system may further comprise a remote server receiving the biometric data from the local computing device. One or more of the local computing device or the remote server may comprise a machine learning algorithm which generates one or more of the cardiac health score or the one or more recommendations or goals for the user. The remote server may be configured for access by a medical professional. Alternatively or in combination, one or more of the cardiac health score or one or more recommendations or goals may be generated by the medical professional and provided to the local computing device through the remote server.
The sensor may comprise one or more of a hand-held electrocardiogram (ECG) sensor, a wrist-worn activity sensor, a blood pressure monitor, a personal weighing scale, a body fat percentage sensor, a personal thermometer, a pulse oximeter sensor, or any mobile health monitor or sensor. Often, the sensor is configured to be in wireless communication with the local computing device. The local computing device comprises one or more of a personal computer, a laptop computer, a palmtop computer, a tablet computer, a smartphone, a body-worn computer, or the like. The biometric data may comprise one or more of an electrocardiogram (ECG), dietary information, stress level, activity level, gender, height, weight, age, body fat percentage, or blood pressure.
Other physiological signals or parameters such as physical activity, heart sounds, blood pressure, blood oxygenation, blood glucose, temperature, activity, breath composition, weight, hydration levels, an electroencephalograph (EEG), an electromyography (EMG), a mechanomyogram (MMG), an electrooculogram (EOG), etc. may also be monitored. The user may also input user-related health data such as age, height, weight, body mass index (BMI), diet, sleep levels, rest levels, or stress levels. One or more of these physiological signals and/or parameters may be combined with the heart rate data to detect atrial fibrillation or other conditions. The machine learning algorithm may be configured to identify atrial fibrillation or other conditions in response to heart rate data in combination with one or more of the other physiological signals and/or parameters for instance. Triggers or alerts may be provided to the user in response to the measured physiological signals and/or parameters. Such triggers or alerts may notify the user to take corrective steps to improve their health or monitor other vital signs or physiological parameters. The application loaded onto and executed on the portable computing device may provide a health dash board integrating and displaying heart rate information, heart health parameters determined in response to the heart rate information, other physiological parameters and trends thereof, and recommended user action items or steps to improve health.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The novel features of the subject matter disclosed herein are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
Devices, systems, and methods for managing health and disease such as cardiac diseases, including arrhythmia and atrial fibrillation, are disclosed. In particular, a cardiac disease and/or rhythm management system, according to aspects of the present disclosure, allows a user to conveniently document their electrocardiograms (ECG) and other biometric data and receive recommendation(s) and/or goal(s) generated by the system or by a physician in response to the documented data.
The term “atrial fibrillation,” denoting a type of cardiac arrhythmia, may also be abbreviated in either the figures or description herein as “AFIB.”
The local computing device 101 may be coupled to one or more biometric sensors. For example, the local computing device 101 may be coupled to a handheld ECG monitor 103. The handheld ECG monitor 103 may be in the form of a smartphone case as described in co-owned U.S. patent application Ser. No. 12/796,188 (now U.S. Pat. No. 8,509,882), Ser. Nos. 13/107,738, 13/420,520 (now U.S. Pat. No. 8,301,232), Ser. Nos. 13/752,048, 13/964,490, 13/969,446, 14/015,303, and 14/076,076, the contents of which are incorporated herein by reference.
In some embodiments, the handheld ECG monitor 103 may be a handheld sensor coupled to the local computing device 101 with an intermediate protective case/adapter as described in U.S. Provisional Application No. 61/874,806, filed Sep. 6, 2013, the contents of which are incorporated herein by reference. The handheld ECG monitor 103 may be used by the user to take an ECG measurement which the handheld ECG monitor 103 may send to the local computing device by connection 103a. The connection 103a may comprise a wired or wireless connection (e.g. a WiFi connection, a Bluetooth connection, a NFC connection, an ultrasound signal transmission connection, etc.). The mobile software application 101a may be configured to interface with the one or more biometric sensors including the handheld ECG monitor 103.
The local computing device 101 may be coupled to a wrist-worn biometric sensor 105 through a wired or wireless connection 105a (e.g. a WiFi connection, a Bluetooth connection, a NFC connection, an ultrasound signal transmission connection, etc.). The wrist-worn biometric sensor 105 may comprise an activity monitor such as those available from Fitbit Inc. of San Francisco, Calif. or a Nike FuelBand available from Nike, Inc. of Oregon. The wrist-worn biometric sensor 105 may also comprise an ECG sensor such as that described in co-owned U.S. Provisional Application No. 61/872,555, the contents of which is incorporated herein by reference.
The local computing device 101 may be coupled to other biometric devices as well such as a personal scale or a blood pressure monitor 107. The blood pressure monitor 107 may communicate with the local device 101 through a wired or wireless connection 107a (e.g. a WiFi connection, a Bluetooth connection, a NFC connection, an ultrasound signal transmission connection, etc.).
The local computing device 101 may directly communicate with a remote server or cloud-based service 113 through the Internet 111 via a wired or wireless connection 111a (e.g. a WiFi connection, a cellular network connection, a DSL Internet connection, a cable Internet connection, a fiber optic Internet connection, a T1 Internet connection, a T3 Internet connection, etc.). Alternatively or in combination, the local computing device 101 may first couple with another local computing device 109 of the user, such as a personal computer of the user, which then communicates with the remote server or cloud-based service 113 via a wired or wireless connection 109a (e.g. a WiFi connection, a cellular network connection, a DSL Internet connection, a cable Internet connection, a fiber optic Internet connection, a T1 Internet connection, a T3 Internet connection, etc.) The local computing device 109 may comprise software or other interface for managing biometric data collected by the local computing device 101 or the biometric data dashboard loaded on the local computing device 101.
Other users may access the patient data through the remote server or cloud-based service 113. These other users may include the user's regular physician, the user's prescribing physician who prescribed the system 100 for use by the user, other cardiac technicians, other cardiac specialists, and system administrators and managers. For example, a first non-subject user may access the remote server or cloud-based service 113 with a personal computer or other computing device 115 through an Internet connection 115a (e.g. a WiFi connection, a cellular network connection, a DSL Internet connection, a cable Internet connection, a fiber optic Internet connection, a T1 Internet connection, a T3 Internet connection, etc.). Alternatively or in combination, the first non-subject user may access the remote server or cloud-based service 113 with a local computing device such as a tablet computer or smartphone 117 through an Internet connection 117a. The tablet computer or smartphone 117 of the first non-subject user may interface with the personal computer 115 through a wired or wireless connection 117b (e.g. a WiFi connection, a Bluetooth connection, a NFC connection, an ultrasound signal transmission connection, etc.). Further, a second non-subject user may access the remote server or cloud-based service 113 with a personal computer or other computing device 119 through an Internet connection 119a (e.g. a WiFi connection, a cellular network connection, a DSL Internet connection, a cable Internet connection, a fiber optic Internet connection, a T1 Internet connection, a T3 Internet connection, etc.). Further, a third non-subject user may access the remote server or cloud-based service 113 with a tablet computer or smartphone 121 through an Internet connection 121a (e.g. a WiFi connection, a cellular network connection, a DSL Internet connection, a cable Internet connection, a fiber optic Internet connection, a T1 Internet connection, a T3 Internet connection, etc.). Further, a fourth non-subject user may access the remote server or cloud-based service 113 with a personal computer or other computing device 123 through an Internet connection 123a (e.g. a WiFi connection, a cellular network connection, a DSL Internet connection, a cable Internet connection, a fiber optic Internet connection, a T1 Internet connection, a T3 Internet connection, etc.). The first non-subject user may comprise an administrator or manager of the system 100. The second non-subject user may comprise a cardiac technician. The third non-subject user may comprise a regular or prescribing physician of the user or subject. And, the fourth non-subject user may comprise a cardiac specialist who is not the user or subject's regular or prescribing physician. Generally, many if not all of the communication between various devices, computers, servers, and cloud-based services will be secure and HIPAA-compliant.
Aspects of the present disclosure provide systems and methods for detecting and/or predicting atrial fibrillation or other arrhythmias of a user by applying one or more machine learning-based algorithms. A portable computing device (or an accessory usable with the portable computing device) may provide R-R intervals and/or raw heart rate signals as input to an application loaded and executed on the portable computing device. The raw heart rate signals may be provided using an electrocardiogram (ECG) in communication with the portable computing device or accessory such as described in U.S. Ser. No. 13/964,490 filed Aug. 12, 2013, Ser. No. 13/420,520 filed Mar. 14, 2013, Ser. No. 13/108,738 filed May 16, 2011, and Ser. No. 12/796,188 filed Jun. 8, 2010. Alternatively or in combination, the raw heart rate signals may be provided using an on-board heart rate sensor of the portable computing device or by using photoplethysmography implemented by an imaging source and a light source of the portable computing device. Alternatively or in combination, the raw heart rate signals may be from an accessory device worn by the user or attached to the user (e.g. a patch) and which is in communication with the portable computing device. Such wearable accessory devices may include Garmin's Vivofit Fitness Band, Fitbit, Polar Heart Rate Monitors, New Balance's Balance Watch, Basis B1 Band, MIO Alpha, Withings Pulse, LifeCORE Heart Rate Monitor strap, and the like.
R-R intervals may be extracted from the raw heart rate signals. The R-R intervals may be used to calculate heart rate variability (HRV) which may be analyzed in many ways such as using time-domain methods, geometric methods, frequency-domain methods, non-linear methods, long term correlations, or the like as known in the art. Alternatively or in combination, the R-R intervals may be used for non-traditional measurements such as (i) determining the interval between every other or every three R-waves to evaluate for bigeminy or trigeminy or (ii) the generation of a periodic autoregressive moving average (PARMA).
The machine learning based algorithm(s) may allow software application(s) to identify patterns and/or features of the R-R interval data and/or the raw heart rate signals or data to predict and/or detect atrial fibrillation or other arrhythmias. These extracted and labelled features may be features of HRV as analyzed in the time domain such as SDNN (the standard deviation of NN intervals calculated over a 24 hour period), SDANN (the standard deviation of the average NN intervals calculated over short periods), RMSSD (the square root of the mean of the sum of the squares of the successive differences between adjacent NNs), SDSD (the standard deviation of the successive differences between adjacent NNs), NN50 (the number of pairs of successive NNs that differ by more than 50 ms), pNN50 (the proportion of NN50 divided by total number of NNs), NN20 (the number of pairs of successive NNs that differ by more than 20 ms), pNN20 (the proportion of NN20 divided by the total number of NNs), EBC (estimated breath cycle), NNx (the number of pairs of successive NNs that differ by more than x ms), pNNx (the proportion of NNx divided by the number of NNs), or other features known in the art. Alternatively or in combination, the extracted and labelled features may comprise a nonlinear transform of R-R ratio or R-R ratio statistics with an adaptive weighting factor. Alternatively or in combination, the extracted and labelled features may be features of HRV as analyzed geometrically such as the sample density distribution of NN interval durations, the sample density distribution of differences between adjacent NN intervals, a Lorenz plot of NN or RR intervals, degree of skew of the density distribution, kurtosis of the density distribution, or other features known in the art. Alternatively or in combination, the extracted and labelled features may be features of HRV in the frequency domain such as the power spectral density of different frequency bands including a high frequency band (HF, from 0.15 to 0.4 Hz), low frequency band (LF, from 0.04 to 0.15 Hz), and the very low frequency band (VLF, from 0.0033 to 0.04 Hz), or other frequency domain features as known in the art. Alternatively or in combination, the extracted and labelled features may be non-linear features such as the geometric shapes of a Poincaré plot, the correlation dimension, the nonlinear predictability, the pointwise correlation dimension, the approximate entropy, and other features as known in the art. Other features from the raw heart rate signals and data may also be analyzed. These features include for example a generated autoregressive (AR) model, a ratio of consecutive RR intervals, a normalized ratio of consecutive RR intervals, a standard deviation of every 2, 3, or 4 RR intervals, or a recurrence plot of the raw HR signals, among others.
The features of the analysis and/or measurement may be selected, extracted, and labelled to predict atrial fibrillation or other arrhythmias in real time, e.g. by performing one or more machine learning operation. Such operations can be selected from among an operation of ranking the feature(s), classifying the feature(s), labelling the feature(s), predicting the feature(s), and clustering the feature(s). Alternatively or in combination, the extracted features may be labelled and saved for offline training of a machine learning algorithm or set of machine learning operations. For example, the operations may be selected from any of those above. Any number of machine learning algorithms or methods may be trained to identify atrial fibrillation or other conditions such as arrhythmias. These may include the use of decision tree learning such as with a random forest, association rule learning, artificial neural network, inductive logic programming, support vector machines, clustering, Bayesian networks, reinforcement learning, representation learning, similarity and metric learning, sparse dictionary learning, or the like.
The systems and methods for detecting and/or predicting atrial fibrillation or other conditions such as arrhythmias described herein may be implemented as software provided as a set of instructions on a non-transitory computer readable medium. A processor of a computing device (e.g. a tablet computer, a smartphone, a smart watch, a smart band, a wearable computing device, or the like) may execute this set of instructions to receive the input data and detect and/or predict atrial fibrillation therefrom. The software may be downloaded from an online application distribution platform such as the Apple iTunes or App Store, Google Play, Amazon App Store, and the like. A display of the computing device may notify the user whether atrial fibrillation or other arrhythmias has been detected and/or if further measurements are required (e.g. to perform a more accurate analysis). The software may be loaded on and executed by the portable computing device of the user such as with the processor of the computing device.
The machine learning-based algorithms or operations for predicting and/or detecting atrial fibrillation or other arrhythmias may be provided as a service from a remote server which may interact or communicate with a client program provided on the computing device of the user, e.g. as a mobile app. The interaction or communication may be through an Application Program Interface (API). The API may provide access to machine learning operations for ranking, clustering, classifying, and predicting from the R-R interval and/or raw heart rate data, for example.
The machine learning-based algorithms or operations, provided through a remote server and/or on a local application on a local computing device, may operate on, learn from, and make analytical predictions from R-R interval data or raw heart rate data, e.g. from a population of users. The R-R interval or raw heart rate data may be provided by the local computing device itself or an associated accessory, such as described in U.S. Ser. No. 13/964,490 filed Aug. 12, 2013, Ser. No. 13/420,520 filed Mar. 14, 2013, Ser. No. 13/108,738 filed May 16, 2011, and Ser. No. 12/796,188 filed Jun. 8, 2010. Thus, atrial fibrillation and other arrhythmias or other heart conditions can be in a convenient, user-accessible way.
Although the above steps show methods 200 and 300 in accordance with many embodiments, a person of ordinary skill in the art will recognize many variations based on the teaching described herein. The steps may be completed in a different order. Steps may be added or deleted. Some of the steps may comprise sub-steps. Many of the steps may be repeated as often as beneficial to the user or subject.
One or more of the steps of method 200 and 300 may be performed with circuitry, for example, one or more of a processor or a logic circuitry such as a programmable array logic for a field programmable gate array. The circuitry may be programmed to provide one or more of the steps of methods 200 and 300, and the program may comprise program instructions stored on a non-transitory computer readable medium or memory or programmed steps of the logic circuitry such as the programmable array logic or the field programmable gate array, for example.
Aspects of the present disclosure provide systems and methods for monitoring one or more physiological parameters and providing a trigger message to the user if the one or more physiological parameter meets a pre-determined or learned threshold(s). Two or more of the physiological parameters may be combined to provide a trigger message. That is, a particular trigger message may be provided to the user if two or more pre-determined threshold(s) for the physiological parameter(s) are met.
Table 1 below shows an exemplary table of physiological parameters that may be measured (left column), features of interest to be measured or threshold types to be met (middle column), and exemplary trigger messages (right column).
The machine learning based algorithms or operations as described herein may be used to determine the appropriate trigger thresholds in response to the raw physiological data input and/or user-input physiological parameters (e.g. age, height, weight, gender, etc.). Features of the raw physiological data input may be selected, extracted, labelled, clustered, and/or analyzed. These processed features may then be analyzed using one or more machine learning operation such as ranking the feature(s), classifying the feature(s), predicting the feature(s), and clustering the feature(s). The various machine learning algorithms described herein may be used to analyze the features to detect and predict health conditions and generate recommendations or user action items to improve the health of the user. For instance, the machine learning algorithms may be trained to identify atrial fibrillation or other conditions in response to the non-heart rate physiological parameter(s) such as age, gender, body mass index (BMI), activity level, diet, and others in combination with the raw heart rate data and HRV that can be extracted therefrom.
The systems and methods for monitoring one or more physiological parameters and providing a trigger message to the user if the one or more physiological parameter meets a pre-determined threshold(s) described herein may be implemented as software provided as a set of instructions on a non-transitory computer readable medium. A processor of a computing device (e.g. a tablet computer, a smartphone, a smart watch, a smart band, a wearable computing device, or the like) may execute this set of instructions to receive the input data and detect and/or predict atrial fibrillation therefrom. The software may be downloaded from an online application distribution platform such as the Apple iTunes or App Store, Google Play, Amazon App Store, and the like. The software may be loaded on and executed by the portable computing device of the user such as with the processor of the computing device. The software may also provide both the triggering application described herein and the heart rate monitoring and analysis for detecting atrial fibrillation or other heart conditions described herein.
In an embodiment, a method and system for longitudinal monitoring of a patient's or any consumer's (after referred to as “patient”) health using various ECG monitoring devices is described herein. The ECG monitoring devices generate ECG signal data which can be stored in a database for further analysis. The ECG data, which can be stored in a database along with other patient information, can be analyzed by a processing device, such as a computer or server, using various algorithms.
Various ECG monitoring or recording devices, hereinafter referred to as ECG monitoring devices, can be used to record the ECG data. For example, the ECG monitoring device can be a handheld, portable, or wearable smartphone based device, as described in U.S. Pat. No. 8,301,232, which is herein incorporated by reference in its entirety for all purposes. A smartphone based device, or a device having wireless or cellular telecommunication capabilities, can transmit the ECG data to a database or server directly through the internet. These types of ECG monitoring devices as well as other ECG monitoring devices include portable devices, wearable recording devices, event recorders, and Holter monitors. Clinical or hospital based ECG recording devices can also be used and integrated into the system. Such devices may be able to transmit stored ECG data through a phone line or wirelessly through the internet or cellular network, or may need to be sent to a data collection center for data collection and processing. The ECG data can be tagged with the type of ECG monitoring device used to record the data by, for example, including it in metadata for indexing and searching purposes.
The ECG monitoring devices can be single lead devices or multiple lead devices, where each lead generally terminates with an electrode. Some embodiments may even be leadless and have electrodes that are integrated with the body or housing of the device, and therefore have a predetermined relationship with each other, such as a fixed spacing apart from each other. The orientation and positioning of the single lead in a single lead device or of each lead of the multiple lead device or of the electrodes of the leadless device can be transmitted with the ECG data. The lead and/or electrode placement may be predetermined and specified to the patient in instructions for using the device. For example, the patient may be instructed to position the leads and/or electrodes with references to one or more anatomical landmarks on the patient's torso. Any deviation from the predetermined lead and/or electrode placement can be notated by the patient or user when transmitting the ECG data. The lead and electrode placement may be imaged using a digital camera, which may be integrated with a smart phone, and transmitted with the ECG data and stored in the database. The lead and electrode placement may be marked on the patient's skin for imaging and for assisting subsequent placement of the leads and electrodes. The electrodes can be attached to the skin using conventional methods which may include adhesives and conducting gels, or the electrodes may simply be pressed into contact with the patient's skin. The lead and electrode placement may be changed after taking one recording or after recording for a predetermined or variable amount of time. The ECG data can be tagged with the numbers of leads and/or electrodes and the lead and/or electrode placement, including whether adhesives and/or conducting gels were used. Again, this information can be including in metadata for indexing and searching purposes.
The ECG signal data can be continuously recorded over a predetermined or variable length of time. Continuous ECG recording devices can record for up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days. Alternatively or additionally, the ECG data can be recorded on demand by the patient at various discrete times, such as when the patient feels chest pains or experiences other unusual or abnormal feelings. The on demand ECG recorder can have a memory buffer that can record a predetermined amount of ECG data on a rolling basis, and when activated by the patient to record a potential event, a predetermined amount of ECG data can be saved and/or transmitted. The predetermined amount of ECG data can include a predetermined amount of ECG data before activation and a predetermined amount of ECG data after activation such that a window of ECG data is captured that encompasses the potential event. The time period between ECG recordings may be regular or irregular. For example, the time period may be once a day, once a week, once a month, or at some other predetermined interval. The ECG recordings may be taken at the same or different times of days, under similar or different circumstances, as described herein. One or more baseline ECGs can be recorded while the patient is free of symptoms. The baseline ECGs can be periodically recorded and predetermined intervals and/or on-demand. The same ECG recording device or different ECG recording devices may be used to record the various ECG of a particular patient. All this information may be tagged to or associated with the ECG data by, for example, including it in the metadata for indexing and searching purposes.
The ECG data can be time stamped and can be annotated by the patient or health care provider to describe the circumstances during which the ECG was recorded, preceding the ECG recording, and/or following the ECG recording. For example, the system and device can have an user interface for data entry that allows the patient to enter in notes regarding the conditions and circumstances surrounding the ECG recording. This additional data can be also included as metadata for indexing and searching purposes. For example, location, food, drink, medication and/or drug consumption, exercise, rest, sleep, feelings of stress, anxiety, pain or other unusual or abnormal feelings, or any other circumstance that may affect the patient's ECG signal can all be inputted into the device, smart phone, computer or other computing device to be transmitted to the server or database along with the ECG data. The annotated data can also include the patient's identity or unique identifier as well as various patient characteristics including age, sex, race, ethnicity, and relevant medical history. The annotated data can also be time stamped or tagged so that the ECG data can be matched or correlated with the activity or circumstance of interest. This also allows comparison of the ECG before, after and during the activity or circumstance so that the effect on the ECG can be determined.
The ECG data and the associated metadata can be transmitted from the device to a server and database for storage and analysis. The transmission can be real-time, at regular intervals such as hourly, daily, weekly and any interval in between, or can be on demand. The metadata facilitates the searching, organizing, analyzing and retrieving of ECG data. Comparison and analysis of a single patient's ECG data can be performed, and/or comparison of ECG data between patients can be performed. For example, the metadata can be used to identify and select a subset of ECG data where an activity or circumstance, such as the taking of medication, occurred within a predetermined amount of time to the ECG data. The components of the ECG signal data, such as the P wave, T wave, and QRS complex and the like, the amplitudes of the components, the ratios between the components, the width of the components, and the delay or time separation between the components, can be extracted, compared, analyzed, and stored as ECG features. For example, the P wave and heart rate can be extracted and analyzed to identify atrial fibrillation, where the absence of P waves and/or an irregular heart rate may indicate atrial fibrillation. The extracted ECG features can also be included in the metadata for indexing and searching.
The changes in the ECG signal over time in view of the activities and circumstances can be compared with changes over time and circumstances observed within a database of ECG's. Comparisons may include any comparison of data derived from any other ECG signal or any database of ECG's or any subset of ECG data, or with data derived from any database of ECG's. Changes in any feature of the ECG signal over time may be used for a relative comparison with similar changes in any ECG database or with data derived from an ECG database. The ECG data from the baseline ECG and the ECG data from a potential adverse event can be compared to determine the changes or deviations from baseline values. In addition, both the baseline ECG and the ECG data recorded from the patient can be compared to one or more predetermined template ECGs which can represent a normal healthy condition as well as various diseased conditions, such as myocardial infarction and arrhythmias.
The comparisons and analysis described herein can be used to draw conclusions and insights into the patient's health status, which includes potential health issues that the patient may be experiencing at the time of measurement or at future times. Conclusions and determinations may be predictive of future health conditions or diagnostic of conditions that the patient already has. The conclusions and determinations may also include insights into the effectiveness or risks associated with drugs or medications that the patient may be taking, have taken or may be contemplating taking in the future. In addition, the comparisons and analysis can be used to determine behaviors and activities that may reduce or increase risk of an adverse event. Based on the comparisons and analysis described herein, the ECG data can be classified according to a level of risk of being an adverse event. For example, the ECG data can be classified as normal, low risk, moderate risk, high risk, and/or abnormal. The normal and abnormal designation may require health care professional evaluation, diagnosis, and/or confirmation.
Diagnosis and determination of an abnormality, an adverse event, or a disease state by physicians and other health care professionals can be transmitted to the servers and database to be tagged with and associated with the corresponding ECG data. The diagnosis and determination may be based on analysis of ECG data or may be determined using other tests or examination procedures. Professional diagnosis and determinations can be extracted from the patient's electronic health records, can be entered into the system by the patient, or can be entered into the system by the medical professional. The conclusions and determinations of the system can be compared with actual diagnosis and determinations from medical professions to validate and/or refine the machine learning algorithms used by the system. The time of occurrence and duration of the abnormality, adverse event or disease state can also be included in the database, such that the ECG data corresponding with the occurrence and/or the ECG data preceding and/or following the abnormality, adverse event or disease state can be associated together and analyzed. The length of time preceding or following the abnormality may be predetermined and be up to 1 to 30 days, or greater than 1 to 12 months. Analysis of the time before the abnormality, adverse event or disease state may allow the system to identify patterns or correlations of various ECG features that precede the occurrence of the abnormality, adverse event or disease state, thereby providing advance detection or warning of the abnormality, adverse event or disease state. Analysis of the time following the abnormality, adverse event or disease state can provide information regarding the efficacy of treatments and/or provide the patient or physician information regarding disease progression, such as whether the patient's condition in improving, worsening or staying the same. The diagnosis and determination can also be used for indexing by, for example, including it in the metadata associated with the corresponding ECG data.
As described herein, various parameters may be included in the database along with the ECG data. These may include the patient's age, gender, weight, blood pressure, medications, behaviors, habits, activities, food consumption, drink consumption, drugs, medical history and other factors that may influence a patient's ECG signal. The additional parameters may or may not be used in the comparison of the changes in ECG signal over time and circumstances.
The conclusions, determinations, and/or insights into the patient's health generated by the system may be communicated to the patient directly or via the patient's caregiver (doctor or other healthcare professional). For example, the patient can be sent an email or text message that is automatically generated by the system. The email or text message can be a notification which directs the patient to log onto a secure site to retrieve the full conclusion, determination or insight, or the email or text message can include the conclusion, determination or insight. Alternatively or additionally, the email or text message can be sent to the patient's caregiver. The notification may also be provided via an application on a smartphone, tablet, laptop, desktop or other computing device.
As described herein, the system can identify behaviors, habits, activities, foods, drinks, medications, drugs, and the like which are associated with the patient's abnormal ECG readings. In addition to informing the patient of these associations, the system can provide instructions or recommendations to the patient to avoid these behaviors, habits, activities, foods, drinks, medications, drugs, and the like which are associated with the patient's abnormal ECG readings. Similarly, the system can identify behaviors, habits, activities, foods, drinks, medications, drugs, and the like which are associated with normal or improving ECG readings, and can instruct or recommend that the patient perform these behaviors, habits, and activities and/or consume these foods, drinks, medications, and drugs. The patient may avoid a future healthcare issue, as instructed or recommended by the system, by modifying their behavior, habits or by taking any course of action, including but not limited to taking a medication, drug or adhering to a diet or exercise program, which may be a predetermined course of action recommended by the system independent of any analysis of the ECG data, and/or may also result from insights learned through this system and method as described herein. In addition, the insights of the system may relate to general fitness and or mental wellbeing.
The ECG data and the associated metadata and other related data as described herein can be stored in a central database, a cloud database, or a combination of the two. The data can be indexed, searched, and/or sorted according to any of the features, parameters, or criteria described herein. The system can analyze the ECG data of a single patient, and it can also analyze the ECG data of a group of patients, which can be selected according to any of the features, parameters or criteria described herein. When analyzing data from a single patient, it may be desirable to reduce and/or correct for the intra-individual variability of the ECG data, so that comparison of one set of ECG data taken at one particular time with another set of ECG data taken at another time reveals differences resulting from changes in health status and not from changes in the type of ECG recording device used, changes in lead and electrode placement, changes in the condition of the skin (i.e. dry, sweaty, conductive gel applied or not applied), and the like. As described above, consistent lead and electrode placement can help reduce variability in the ECG readings. The system can also retrieve the patient's ECG data that were taken under similar circumstances and can analyze this subset of ECG data.
Although the above steps show a method 400 in accordance with many embodiments, a person of ordinary skill in the art will recognize many variations based on the teaching described herein. The steps may be completed in a different order. Steps may be added or deleted. Some of the steps may comprise sub-steps. Many of the steps may be repeated as often as beneficial to the user or subject.
One or more of the steps of a method 400 may be performed with circuitry, for example, one or more of a processor or a logic circuitry such as a programmable array logic for a field programmable gate array. The circuitry may be programmed to provide one or more of the steps of a method 400, and the program may comprise program instructions stored on a non-transitory computer readable medium or memory or programmed steps of the logic circuitry such as the programmable array logic or the field programmable gate array, for example.
Aspects of the present disclosure provide systems and methods for generating a heart health score in response to continuously measured or monitored physiological parameter(s). The score may be given a quantitative value such as be graded from A to F or 0 to 100 for example (e.g. a great score may be an A or 100, a good score may be a B or 75, a moderate score may be a C or 50, a poor score may be a D or 25, and a failing score may be an F or 0.) If an arrhythmia is detected, the score may be below 50 for example. Other scoring ranges such as A to Z, 1 to 5, 1 to 10, 1 to 1000, etc. may also be used. Arrhythmia may be detecting using the machine learning based operations or algorithms described herein.
In a step 502, an arrhythmia is detected. If an arrhythmia is detected (e.g. using the methods and/or algorithms disclosed herein), then the heart health score generated will be below 50. Depending on the severity of the arrhythmia detected, the heart score may be calculated or assigned within the ranges according to the table below in Table 2.
In a step 504 a Heart Rate Variability (HRV) is calculated. HRV can be an indicator of heart health. The value for HRV value for a healthy heart is typically higher than HRV for an unhealthy heart. Also, HRV typically declines with age and may be affected by other factors, like stress, lack of physical activity, etc. HRV may be measured and analyzed using the methods described above. HRV may be calculated in the absence of arrhythmia, which may improve the accuracy of the HRV measurement. HRV may be determined and further analyzed as described above.
In a step 506, premature beats are counted and Heart Rate Turbulence (HRT) is calculated. Premature beats in the sequence of R-R intervals may be detected. Also, R-R intervals typically tend to recover at a certain pace after a premature beat. Using these two parameters (prematurity and pace of R-R recovery), HRT parameters may be calculated. There may be known deviations of HRT parameters associated with patients with risk of Congestive Heart Failure (CHF). These deviations, however, may be used to estimate an inverse measure. The number of premature beats per day (or per hour) may also be used as a measure of heart health. A low number of premature beats may indicate better heart health. In summary, the heart health score may be generated by combining at least heart rate variability (HRV), the number of premature beats, and heart rate turbulence (HRT). This combination (in the absence of arrhythmia) may provide an accurate estimate of how healthy the heart of the user is.
In a step 508, a heart health score is generated, and in a step 510, a hearth health score is generated based on an arrhythmia. To initially generate the score, a few hours (e.g. 2-5 hours) of measured R-R intervals may be required. A more accurate score may be generated after a week of continuous R-R interval measurements. Longer data sets may be required to detect significant arrhythmias as they may usually be detected within the first 7-8 days of monitoring.
Although the above steps show a method 500 in accordance with many embodiments, a person of ordinary skill in the art will recognize many variations based on the teaching described herein. The steps may be completed in a different order. Steps may be added or deleted. Some of the steps may comprise sub-steps. Many of the steps may be repeated as often as beneficial to the user or subject.
One or more of the steps of a method 500 may be performed with circuitry, for example, one or more of a processor or a logic circuitry such as a programmable array logic for a field programmable gate array. The circuitry may be programmed to provide one or more of the steps of a method 500, and the program may comprise program instructions stored on a non-transitory computer readable medium or memory or programmed steps of the logic circuitry such as the programmable array logic or the field programmable gate array, for example.
In a step 602, a raw ECG waveform is obtained. In a step 608, ECG parameters are extracted from the raw ECG waveform data and arrhythmia prediction and/or detection algorithms are run to analyze the obtained raw ECG waveform data.
In a step 604, physiological parameters may be measured using a sensor of the user's local computing device or an accessory thereof. Such measured physiological parameters may include blood pressure, user activity and exercise level, blood oxygenation levels, blood sugar levels, an electrocardiogram, skin hydration or the like of the user. These physiological parameters may be measured over time such as over substantially the same time scale or length as the measurement of heart rate. In a step 610, an R-R interval is extracted and both traditional and non-traditional heart rate measures are used to analyze the measured heart rate and physiological parameters.
In a step 606, additional physiological parameters for determining the heart health score may be input by the user. These parameters may include the age, the gender, the weight, the height, the body type, the body mass index (BMI), the personal medical history, the family medical history, the exercise and activity level, the diet, the hydration level, the amount of sleep, the cholesterol level, the alcohol intake level, the caffeine intake level, the smoking status, and the like of the user. For example, the heart health score may be weighted by age and/or gender to provide the user an accurate assessment of his or her heart health in response to the heart rate data. In a step 612, feature extraction is used to analyze the inputted physiological parameters.
In a step 614 feature ranking and/or feature selection occurs. In a step 618, a real time prediction or detection of atrial fibrillation, and/or in a step 616, the heart rate variability measurements may be labelled and saved for offline training of a machine learning algorithm or set of machine learning operations, and then may be subsequently used to make a real time prediction and/or detection of atrial fibrillation. A plurality of heart health scores may be generated by a plurality of users to generate a set of population data. This population data may be used to train the machine learning algorithms described herein such that the trained algorithm may be able to detect and predict atrial fibrillation or other health conditions from user data.
Although the above steps show a method 600 in accordance with many embodiments, a person of ordinary skill in the art will recognize many variations based on the teaching described herein. The steps may be completed in a different order. Steps may be added or deleted. Some of the steps may comprise sub-steps. Many of the steps may be repeated as often as beneficial to the user or subject.
One or more of the steps of a method 600 may be performed with circuitry, for example, one or more of a processor or a logic circuitry such as a programmable array logic for a field programmable gate array. The circuitry may be programmed to provide one or more of the steps of a method 600, and the program may comprise program instructions stored on a non-transitory computer readable medium or memory or programmed steps of the logic circuitry such as the programmable array logic or the field programmable gate array, for example.
The systems and methods for generating a heart health score in response to continuously measured or monitored physiological parameter(s) may comprise a processor of a computing device and software. A processor of a computing device (e.g. a tablet computer, a smartphone, a smart watch, a smart band, a wearable computing device, or the like) may execute this set of instructions to receive the input data and detect and/or predict atrial fibrillation therefrom. The software may be downloaded from an online application distribution platform such as the Apple iTunes or App Store, Google Play, Amazon App Store, and the like. A display of the computing device may notify the user of the calculated heart health score and/or if further measurements are required (e.g. to perform a more accurate analysis).
In a step 906, the user or subject downloads the cardiac disease and/or rhythm management system software onto their computing device. For example, the system software may comprise a mobile software application (“mobile app”) downloaded from the Apple App Store, Google Play, Amazon Appstore, BlackBerry World, Nokia Store, Windows Store, Windows Phone Store, Samsung Apps Store, and the like. The downloaded system software, e.g. mobile app 101a, may be configured to interface with the biometric sensors provided to the user or subject in the step 154.
In a step 908, personal information input to the cardiac disease management system is received. For example, the user or subject may enter his or her gender, height, weight, diet, disease risk factors, etc. into the mobile app 101a. Alternatively or in combination, this personal information may be input on behalf of the user or subject, for example, by a physician of the user or subject.
In a step 910, biometric data is received from the biometric sensors provided to the user or subject. For example, the system 100 and the mobile app 101a may receive ECG data and heart rate from handheld sensor 103, activity data from wrist-worn activity sensor 105, blood pressure and heart rate data from mobile blood pressure monitor 107a, and other data such as weight and body fat percentage data from a “smart” scale in communication with the local computing device 101.
In a step 912, a cardiac health score is generated. The cardiac health score can be generated by considering and weighing one or more influencing factors including the incidence of atrial fibrillation or arrhythmia as detected by the handheld ECG monitor, the heart rate of the user or subject, the activity of the user or subject, hours of sleep and rest of the user or subject, blood pressure of the user or subject, etc. Often, the incidence of atrial fibrillation or arrhythmia will be weighed the most. The cardiac health score may be generated by a physician or a machine learning algorithm provided by the remote server or cloud-based service 113, for example. A plurality of users and subject may concurrently use the cardiac health and/or rhythm management system 100 and the machine learning algorithm may, for example, consider population data and trends to generate an individual user or subject's cardiac health score.
In a step 914, one or more recommendations or goals is generated for the user or subject based on or in response to the generated cardiac health score. These recommendation(s) and/or goal(s) may be generated automatically based on or in response to the biometric and personal information of the user or subject. For example, the machine learning algorithm may generate these recommendation(s)/goal(s). Alternatively or in combination, a physician or other medical specialist may generate the recommendation(s) and/or goal(s), for example, based on or in response to the biometric and personal information of the user or subject. The physician or other medical professional may access the patient data through the Internet as described above.
In a step 916, the patient implements many if not all of the recommendation(s) and/or goal(s) provided to him or her. And in a step 916, steps 908 to 916 may be repeated such that the user or subject may iteratively improve their cardiac health score and their overall health.
Although the above steps show method 900 of managing cardiac disease and/or rhythm in accordance with many embodiments, a person of ordinary skill in the art will recognize many variations based on the teaching described herein. The steps may be completed in a different order. Steps may be added or deleted. Some of the steps may comprise sub-steps. Many of the steps may be repeated as often as beneficial to the user or subject.
One or more of the steps of the method 900 may be performed with circuitry, for example, one or more of a processor or a logic circuitry such as a programmable array logic for a field programmable gate array. The circuitry may be programmed to provide one or more of the steps of the method 900, and the program may comprise program instructions stored on a non-transitory computer readable medium or memory or programmed steps of the logic circuitry such as the programmable array logic or the field programmable gate array, for example.
In some embodiments, the heart rate information (or an extracted portion of HR information) may be used to compare to a database of similar information that has been correlated with cardiac events. For example, heart rate information may be compared to a database of HR information extracted for ECG recordings of patients known to be experiencing cardiac problems. Thus, patterns of heart rate information taken from a subject may be compared to patterns of cardiac information in a database. If there is a match (or a match within a reasonable closeness of fit), the patient may be instructed to record an ECG, e.g. using an ambulatory ECG monitor. This may then provide a more detailed view of the heart. This method may be particularly useful, as it may allow recording and/or transmission and/or analysis of detailed electrical information about the heart at or near the time (or shortly thereafter) when a clinically significant cardiac event is occurring. Thus, the continuous monitoring may allow a subject to be alerted immediately upon an indication of the potential problem (e.g. an increase in HRV suggestive of a cardiac dysfunction). This may allow the coupling of continuous HR monitoring with ECG recording and analysis for disease diagnosis and disease management.
The top portion 1100a of the atrial fibrillation dashboard 1100 as shown in
The bottom portion 1100b of the atrial fibrillation dashboard 1100 as shown in
A bottom portion 1200b of the goals and recommendations page 1200 may comprise a listing of new goals which the user or subject may add. The new goals may be categorized into goals or recommendations for atrial fibrillation management, stress management, and/or other categories. For example, goals for atrial fibrillation management may include taking daily medications, reducing caffeine intake, and reducing alcohol intake. And, goals for stress management may include meditate for 5 minutes daily, take blood pressure reading daily, and getting at least 7 hours of sleep nightly. Using the goals and recommendations page 1200, the user or subject can set their goals for the week. One or more of these goals may be automatically recommended to the user or subject or be recommended by a physician having access to the dashboard 1100. For example, goals may be recommended based on last week's progress. The completion of recommended goals can result in the user or subject earning more “points,” in effect gamifying health and cardiac rhythm management for the user or subject. Alternatively or in combination, the goals may be set by a physician having access to the dashboard 1100.
For example, presently available smart watches include motion sensors such as pedometers. Pedometers can be based on an accelerometer or electromechanical mechanism such as a pendulum, magnetic reed proximity switch, and a spring suspended lever arm with metal-on-metal contact. Modern accelerometers are often small micro electro-mechanical systems and are well known by those skilled in the art. Heart rate monitors are readily available with smart phones as well as smart watches. One type uses an optical sensor to detect the fluctuation of blood flow. The signal can be amplified further using, for example, a microcontroller to count the rate of fluctuation, which is actually the heart rate.
An advisory condition for recording an ECG may occur due to, for example, large continuing fluctuations in heart rate. An advisory condition for recording an ECG can also occur when a measured heart rate increases rapidly without a corresponding increase in activity monitored by, for example, an accelerometer. By comparing measured heart rate changes with measured activity changes, the presently disclosed software or “app” minimizes false alarms are minimized. ECG devices are described in U.S. Ser. No. 12/796,188, filed Jun. 8, 2010, now U.S. Pat. No. 8,509,882, hereby expressly incorporated herein by reference in its entirety. The ECG device can be present in a smart watch band or a smart phone. In one embodiment, the ECG device includes an electrode assembly configured to sense heart-related signals upon contact with a user's skin, and to convert the sensed heart-related signals to an ECG electric signal. The ECG device transmits an ultrasonic frequency modulated ECG signal to a computing device such as, for example, a smartphone. Software running on the computing device or smartphone digitizes and processes the audio in real-time, where the frequency modulated ECG signal is demodulated. The ECG can be further processed using algorithms to calculate heart rate and identify arrhythmias. The ECG, heart rate, and rhythm information can be displayed on the computer or smartphone, stored locally for later retrieval, and/or transmitted in real-time to a web server via a 2G/3G/4G, WiFi or other Internet connection. In addition to the display and local processing of the ECG data, the computer or smartphone can transmit, in real-time, the ECG, heart rate and rhythm data via a secure web connection for viewing, storage and further analysis via a web browser interface.
In another embodiment, the converter assembly of an ECG device is integrated with, and electrically connected to the electrode assembly and is configured to convert the electric ECG signal generated by electrode assembly to a frequency modulated ECG ultrasonic signal having a carrier frequency in the range of from about 18 kHz to about 24 kHz. It is sometimes desirable to utilize a carrier frequency in the 20 kHz to 24 kHz range. The ultrasonic range creates both a lower noise and a silent communication between the acquisition electronics and the computing device such as the smartphone, notebook, smart watch and the like.
A kit can include downloadable software such as an “app” for detecting an advisory condition for recording an ECG and an ECG device. The ECG device can be present on a watch band for replacing a specific band on a smart watch. The ECG device can also be provided on a smart phone back plate for replacing an existing removable smartphone back. In another configuration, the ECG device is usable as a smartphone protective case.
Software on the smartphone or smart watch can also combine data and signals from other sensors built into the smartphone or smart watch such as a GPS.
While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the subject matter described herein. It should be understood that various alternatives to the embodiments of the subject matter described herein may be employed in practicing the subject matter described herein. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.
This application is a divisional of U.S. application Ser. No. 14/730,122, filed Jun. 3, 2015, which is a continuation of U.S. application Ser. No. 14/569,513 filed Dec. 12, 2014, now U.S. Pat. No. 9,420,956, issued Aug. 23, 2016, which claims the benefit of U.S. Provisional Application No. 61/915,113, filed Dec. 12, 2013, which application is incorporated herein by reference, U.S. Provisional Application No. 61/953,616 filed Mar. 14, 2014, U.S. Provisional Application No. 61/969,019, filed Mar. 21, 2014, U.S. Provisional Application No. 61/970,551 filed Mar. 26, 2014 which application is incorporated herein by reference, and U.S. Provisional Application No. 62/014,516, filed Jun. 19, 2014, which application is incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3717857 | Evans | Feb 1973 | A |
| 3731311 | Williams | May 1973 | A |
| 3768014 | Smith et al. | Oct 1973 | A |
| 3776228 | Semler | Dec 1973 | A |
| 3779237 | Roth et al. | Dec 1973 | A |
| 3779249 | Semler | Dec 1973 | A |
| 3782367 | Hochberg et al. | Jan 1974 | A |
| 3805227 | Lester | Apr 1974 | A |
| 3882277 | Depedro et al. | May 1975 | A |
| 3885552 | Kennedy | May 1975 | A |
| 3898984 | Mandel et al. | Aug 1975 | A |
| 3909599 | Trott, Jr. et al. | Sep 1975 | A |
| 4027146 | Gilmore | May 1977 | A |
| 4045767 | Nishihara et al. | Aug 1977 | A |
| 4083366 | Gombrich et al. | Apr 1978 | A |
| 4095050 | Beachem et al. | Jun 1978 | A |
| 4221223 | Linden | Sep 1980 | A |
| 4230127 | Larson | Oct 1980 | A |
| 4231031 | Crowther et al. | Oct 1980 | A |
| 4250888 | Grosskopf | Feb 1981 | A |
| 4281664 | Duggan | Aug 1981 | A |
| 4295472 | Adams | Oct 1981 | A |
| 4312358 | Barney | Jan 1982 | A |
| 4318130 | Heuer | Mar 1982 | A |
| 4364397 | Citron et al. | Dec 1982 | A |
| 4367752 | Jimenez et al. | Jan 1983 | A |
| 4409984 | Dick | Oct 1983 | A |
| 4531527 | Reinhold, Jr. et al. | Jul 1985 | A |
| 4567883 | Langer et al. | Feb 1986 | A |
| 4572182 | Royse | Feb 1986 | A |
| 4580250 | Kago et al. | Apr 1986 | A |
| 4583553 | Shah et al. | Apr 1986 | A |
| 4622979 | Katchis et al. | Nov 1986 | A |
| 4625730 | Fountain et al. | Dec 1986 | A |
| 4803625 | Fu et al. | Feb 1989 | A |
| 4889131 | Salem et al. | Dec 1989 | A |
| 4920489 | Hubelbank et al. | Apr 1990 | A |
| 4938228 | Righter et al. | Jul 1990 | A |
| 4938229 | Bergelson et al. | Jul 1990 | A |
| 4958641 | Digby et al. | Sep 1990 | A |
| 4977899 | Digby et al. | Dec 1990 | A |
| 4981141 | Segalowitz | Jan 1991 | A |
| 5012814 | Mills et al. | May 1991 | A |
| 5023906 | Novas | Jun 1991 | A |
| 5025794 | Albert et al. | Jun 1991 | A |
| 5058597 | Onoda et al. | Oct 1991 | A |
| 5090418 | Squires et al. | Feb 1992 | A |
| 5111396 | Mills et al. | May 1992 | A |
| 5128552 | Fang et al. | Jul 1992 | A |
| 5136555 | Gardos | Aug 1992 | A |
| 5181552 | Eiermann | Jan 1993 | A |
| 5191891 | Righter | Mar 1993 | A |
| 5201321 | Fulton | Apr 1993 | A |
| 5218969 | Bredesen et al. | Jun 1993 | A |
| 5226424 | Bible | Jul 1993 | A |
| 5238001 | Gallant et al. | Aug 1993 | A |
| D341659 | Homayoun et al. | Nov 1993 | S |
| 5259387 | Depinto | Nov 1993 | A |
| 5301679 | Taylor | Apr 1994 | A |
| 5304186 | Semler et al. | Apr 1994 | A |
| 5313953 | Yomtov et al. | May 1994 | A |
| 5321618 | Gessman | Jun 1994 | A |
| 5333616 | Mills et al. | Aug 1994 | A |
| 5336245 | Adams et al. | Aug 1994 | A |
| 5337752 | Reeves | Aug 1994 | A |
| 5339824 | Engira | Aug 1994 | A |
| 5343869 | Pross et al. | Sep 1994 | A |
| 5343870 | Gallant et al. | Sep 1994 | A |
| 5348008 | Bornn et al. | Sep 1994 | A |
| 5360005 | Wilk | Nov 1994 | A |
| 5365935 | Righter et al. | Nov 1994 | A |
| 5410587 | Grunwell | Apr 1995 | A |
| 5417222 | Dempsey et al. | May 1995 | A |
| 5433736 | Nilsson | Jul 1995 | A |
| 5452356 | Albert | Sep 1995 | A |
| 5466246 | Silvian | Nov 1995 | A |
| 5467773 | Bergelson et al. | Nov 1995 | A |
| 5481255 | Albert et al. | Jan 1996 | A |
| 5503158 | Coppock et al. | Apr 1996 | A |
| 5518001 | Snell | May 1996 | A |
| 5522396 | Langer et al. | Jun 1996 | A |
| 5539705 | Akerman et al. | Jul 1996 | A |
| D372785 | Sabri | Aug 1996 | S |
| 5544661 | Davis et al. | Aug 1996 | A |
| 5551953 | Lattin et al. | Sep 1996 | A |
| 5561712 | Nishihara | Oct 1996 | A |
| 5568448 | Tanigushi et al. | Oct 1996 | A |
| 5579284 | May | Nov 1996 | A |
| D377983 | Sabri et al. | Feb 1997 | S |
| 5608723 | Felsenstein | Mar 1997 | A |
| 5634468 | Platt et al. | Jun 1997 | A |
| 5652570 | Lepkofker | Jul 1997 | A |
| 5661699 | Sutton | Aug 1997 | A |
| 5675325 | Taniguchi et al. | Oct 1997 | A |
| 5678562 | Sellers | Oct 1997 | A |
| 5701894 | Cherry et al. | Dec 1997 | A |
| 5704364 | Saltzstein et al. | Jan 1998 | A |
| 5724025 | Tavori | Mar 1998 | A |
| 5730143 | Schwarzberg | Mar 1998 | A |
| 5735285 | Albert et al. | Apr 1998 | A |
| 5742251 | Gerber | Apr 1998 | A |
| 5748103 | Flach et al. | May 1998 | A |
| 5764763 | Jensen et al. | Jun 1998 | A |
| 5772586 | Heinonen et al. | Jun 1998 | A |
| 5818788 | Kimura et al. | Oct 1998 | A |
| 5825718 | Ueki et al. | Oct 1998 | A |
| 5827179 | Lichter et al. | Oct 1998 | A |
| 5840020 | Heinonen et al. | Nov 1998 | A |
| 5844997 | Murphy, Jr. | Dec 1998 | A |
| 5861018 | Feierbach | Jan 1999 | A |
| 5873369 | Laniado et al. | Feb 1999 | A |
| 5876351 | Rohde | Mar 1999 | A |
| 5877675 | Rebstock et al. | Mar 1999 | A |
| 5889730 | May | Mar 1999 | A |
| 5929761 | Van Der Laan et al. | Jul 1999 | A |
| D414870 | Saltzstein et al. | Oct 1999 | S |
| 5970388 | Will | Oct 1999 | A |
| 5976083 | Richardson et al. | Nov 1999 | A |
| 5982297 | Welle | Nov 1999 | A |
| 5983127 | Depinto | Nov 1999 | A |
| 6008703 | Perrott et al. | Dec 1999 | A |
| 6024705 | Schlager et al. | Feb 2000 | A |
| 6037704 | Welle | Mar 2000 | A |
| 6047206 | Albrecht et al. | Apr 2000 | A |
| 6047257 | Dewaele | Apr 2000 | A |
| 6048319 | Hudgins et al. | Apr 2000 | A |
| D427315 | Saltzstein et al. | Jun 2000 | S |
| 6072396 | Gaukel | Jun 2000 | A |
| 6083248 | Thompson | Jul 2000 | A |
| 6084510 | Lemelson et al. | Jul 2000 | A |
| 6102856 | Groff et al. | Aug 2000 | A |
| 6153532 | Dow et al. | Nov 2000 | A |
| 6159147 | Lichter et al. | Dec 2000 | A |
| 6198394 | Jacobsen et al. | Mar 2001 | B1 |
| 6224548 | Gopinathan et al. | May 2001 | B1 |
| 6236889 | Soykan et al. | May 2001 | B1 |
| 6264614 | Albert et al. | Jul 2001 | B1 |
| 6282440 | Brodnick et al. | Aug 2001 | B1 |
| 6282441 | Raymond et al. | Aug 2001 | B1 |
| 6289238 | Besson et al. | Sep 2001 | B1 |
| 6319201 | Wilk | Nov 2001 | B1 |
| 6343049 | Toda | Jan 2002 | B1 |
| 6363139 | Zurek et al. | Mar 2002 | B1 |
| 6364834 | Reuss et al. | Apr 2002 | B1 |
| 6366871 | Geva | Apr 2002 | B1 |
| 6377843 | Naydenov et al. | Apr 2002 | B1 |
| 6418394 | Puolakanaho et al. | Jul 2002 | B1 |
| 6433689 | Hovind et al. | Aug 2002 | B1 |
| 6453164 | Fuller et al. | Sep 2002 | B1 |
| 6478736 | Mault | Nov 2002 | B1 |
| 6485416 | Platt et al. | Nov 2002 | B1 |
| 6507734 | Berger et al. | Jan 2003 | B1 |
| 6513532 | Mault et al. | Feb 2003 | B2 |
| 6549756 | Engstrom | Apr 2003 | B1 |
| 6558320 | Causey, III et al. | May 2003 | B1 |
| 6579231 | Phipps | Jun 2003 | B1 |
| 6595929 | Stivoric et al. | Jul 2003 | B2 |
| 6600471 | Lee et al. | Jul 2003 | B2 |
| 6605038 | Teller et al. | Aug 2003 | B1 |
| 6612985 | Eiffert et al. | Sep 2003 | B2 |
| 6616613 | Goodman | Sep 2003 | B1 |
| 6636761 | Brodnick | Oct 2003 | B2 |
| 6685633 | Albert et al. | Feb 2004 | B2 |
| 6717983 | Toda | Apr 2004 | B1 |
| 6790178 | Mault et al. | Sep 2004 | B1 |
| 6804558 | Haller et al. | Oct 2004 | B2 |
| 6820057 | Loch et al. | Nov 2004 | B1 |
| 6845263 | Kawaguchi | Jan 2005 | B2 |
| 6893396 | Schulze et al. | May 2005 | B2 |
| 6928535 | Yamashita et al. | Aug 2005 | B2 |
| 6950681 | Hofmann | Sep 2005 | B2 |
| 6970737 | Brodnick et al. | Nov 2005 | B1 |
| 6987965 | Ng et al. | Jan 2006 | B2 |
| 7018339 | Birnbaum et al. | Mar 2006 | B2 |
| 7020508 | Stivoric et al. | Mar 2006 | B2 |
| 7031745 | Shen | Apr 2006 | B2 |
| 7061381 | Forcier et al. | Jun 2006 | B2 |
| 7103407 | Hjelt et al. | Sep 2006 | B2 |
| 7107095 | Manolas | Sep 2006 | B2 |
| 7108659 | Ross et al. | Sep 2006 | B2 |
| 7153262 | Stivoric et al. | Dec 2006 | B2 |
| 7162291 | Nachaliel | Jan 2007 | B1 |
| 7162294 | Rowlandson et al. | Jan 2007 | B2 |
| 7188151 | Kumar et al. | Mar 2007 | B2 |
| 7222054 | Geva | May 2007 | B2 |
| 7236818 | McLeod et al. | Jun 2007 | B2 |
| 7257448 | Crowe et al. | Aug 2007 | B2 |
| 7260429 | Siejko et al. | Aug 2007 | B2 |
| 7261690 | Teller et al. | Aug 2007 | B2 |
| 7285090 | Stivoric et al. | Oct 2007 | B2 |
| 7319425 | Fiorenza et al. | Jan 2008 | B2 |
| 7324836 | Steenstra et al. | Jan 2008 | B2 |
| 7349574 | Sodini et al. | Mar 2008 | B1 |
| 7351207 | Priemer | Apr 2008 | B2 |
| 7354400 | Asafusa et al. | Apr 2008 | B2 |
| 7382247 | Welch et al. | Jun 2008 | B2 |
| 7383297 | Atsmon et al. | Jun 2008 | B1 |
| 7398115 | Lynn | Jul 2008 | B2 |
| 7415304 | Rowlandson et al. | Aug 2008 | B2 |
| 7444116 | Ivanov et al. | Oct 2008 | B2 |
| 7460899 | Almen | Dec 2008 | B2 |
| 7502643 | Farringdon et al. | Mar 2009 | B2 |
| 7509159 | Xue et al. | Mar 2009 | B2 |
| 7515043 | Welch et al. | Apr 2009 | B2 |
| 7515044 | Welch et al. | Apr 2009 | B2 |
| 7520860 | Guion-Johnson et al. | Apr 2009 | B2 |
| 7542878 | Nanikashvili | Jun 2009 | B2 |
| 7548623 | Manabe | Jun 2009 | B2 |
| 7596405 | Kurzweil et al. | Sep 2009 | B2 |
| 7603148 | Michalak | Oct 2009 | B2 |
| 7647185 | Tarassenko et al. | Jan 2010 | B2 |
| 7654148 | Tomlinson et al. | Feb 2010 | B2 |
| 7657479 | Henley | Feb 2010 | B2 |
| 7668589 | Bauer | Feb 2010 | B2 |
| 7689437 | Teller et al. | Mar 2010 | B1 |
| 7701895 | Gehasie et al. | Apr 2010 | B2 |
| 7733224 | Tran | Jun 2010 | B2 |
| 7742808 | Nissila et al. | Jun 2010 | B2 |
| 7806832 | Gallagher et al. | Oct 2010 | B2 |
| 7819814 | Gavriely et al. | Oct 2010 | B2 |
| 7846104 | MacQuarrie et al. | Dec 2010 | B2 |
| 7846106 | Andrews et al. | Dec 2010 | B2 |
| 7904160 | Brodnick et al. | Mar 2011 | B2 |
| 7945064 | O'Brien et al. | May 2011 | B2 |
| 7946959 | Shum et al. | May 2011 | B2 |
| 7955273 | Rahe-Meyer | Jun 2011 | B2 |
| 7983749 | Warren | Jul 2011 | B2 |
| 8019609 | Tamir et al. | Sep 2011 | B2 |
| 8034006 | Celik-Butler et al. | Oct 2011 | B2 |
| 8062090 | Atsmon et al. | Nov 2011 | B2 |
| 8078136 | Atsmon et al. | Dec 2011 | B2 |
| 8078278 | Penner | Dec 2011 | B2 |
| 8126526 | Kitajima et al. | Feb 2012 | B2 |
| 8126566 | Stahmann et al. | Feb 2012 | B2 |
| 8126728 | Dicks et al. | Feb 2012 | B2 |
| 8130093 | Mazar et al. | Mar 2012 | B2 |
| 8150750 | Ray | Apr 2012 | B2 |
| 8160276 | Liao et al. | Apr 2012 | B2 |
| 8165677 | Von et al. | Apr 2012 | B2 |
| 8216136 | Addison et al. | Jul 2012 | B2 |
| 8224429 | Prstojevich et al. | Jul 2012 | B2 |
| 8265907 | Nanikashvili et al. | Sep 2012 | B2 |
| 8275553 | Ochs et al. | Sep 2012 | B2 |
| 8275635 | Stivoric et al. | Sep 2012 | B2 |
| 8282550 | Rasdal et al. | Oct 2012 | B2 |
| 8285356 | Bly et al. | Oct 2012 | B2 |
| 8301232 | Albert et al. | Oct 2012 | B2 |
| 8301236 | Baumann et al. | Oct 2012 | B2 |
| 8323188 | Tran | Dec 2012 | B2 |
| 8328718 | Tran | Dec 2012 | B2 |
| 8332233 | Ott et al. | Dec 2012 | B2 |
| 8364250 | Moon et al. | Jan 2013 | B2 |
| 8369936 | Farringdon et al. | Feb 2013 | B2 |
| 8374688 | Libbus et al. | Feb 2013 | B2 |
| 8449471 | Tran | May 2013 | B2 |
| 8500636 | Tran | Aug 2013 | B2 |
| 8509882 | Albert et al. | Aug 2013 | B2 |
| 8519835 | Dunko | Aug 2013 | B2 |
| 8543185 | Yuen et al. | Sep 2013 | B2 |
| 8548577 | Muhlsteff et al. | Oct 2013 | B2 |
| 8548770 | Yuen et al. | Oct 2013 | B2 |
| 8700137 | Albert | Apr 2014 | B2 |
| 8725229 | Furue et al. | May 2014 | B2 |
| 8755871 | Weng et al. | Jun 2014 | B2 |
| 8823490 | Libbus et al. | Sep 2014 | B2 |
| 8923958 | Gupta et al. | Dec 2014 | B2 |
| 8951189 | Osorio | Feb 2015 | B2 |
| 8951192 | Osorio | Feb 2015 | B2 |
| 8974396 | Brady et al. | Mar 2015 | B1 |
| 8977347 | Mestha et al. | Mar 2015 | B2 |
| 9026202 | Albert | May 2015 | B2 |
| 9220430 | Albert | Dec 2015 | B2 |
| 9254095 | Galloway et al. | Feb 2016 | B2 |
| 9351654 | Albert | May 2016 | B2 |
| 9420956 | Gopalakrishnan et al. | Aug 2016 | B2 |
| 9572499 | Gopalakrishnan et al. | Feb 2017 | B2 |
| 20010027384 | Schulze et al. | Oct 2001 | A1 |
| 20010031998 | Nelson et al. | Oct 2001 | A1 |
| 20010051766 | Gazdzinski | Dec 2001 | A1 |
| 20020016541 | Glossop | Feb 2002 | A1 |
| 20020032386 | Sackner et al. | Mar 2002 | A1 |
| 20020111556 | Wegner | Aug 2002 | A1 |
| 20020143576 | Nolvak et al. | Oct 2002 | A1 |
| 20030004425 | Narimatsu et al. | Jan 2003 | A1 |
| 20030093002 | Kuo | May 2003 | A1 |
| 20030107487 | Korman et al. | Jun 2003 | A1 |
| 20030117987 | Brebner | Jun 2003 | A1 |
| 20030149344 | Nizan | Aug 2003 | A1 |
| 20030193839 | Singh | Oct 2003 | A1 |
| 20040034284 | Aversano et al. | Feb 2004 | A1 |
| 20040044292 | Yasushi et al. | Mar 2004 | A1 |
| 20040059205 | Carlson et al. | Mar 2004 | A1 |
| 20040117212 | Kong et al. | Jun 2004 | A1 |
| 20040120356 | Davenport et al. | Jun 2004 | A1 |
| 20040143403 | Brandon et al. | Jul 2004 | A1 |
| 20040215088 | Hubelbank | Oct 2004 | A1 |
| 20040215094 | Baumer et al. | Oct 2004 | A1 |
| 20040220487 | Vyshedskiy et al. | Nov 2004 | A1 |
| 20040220488 | Vyshedskiy et al. | Nov 2004 | A1 |
| 20040225199 | Evanyk et al. | Nov 2004 | A1 |
| 20040228217 | Szeto | Nov 2004 | A1 |
| 20040236819 | Anati et al. | Nov 2004 | A1 |
| 20040266407 | Lee et al. | Dec 2004 | A1 |
| 20040266480 | Hjelt et al. | Dec 2004 | A1 |
| 20050014531 | Findikli | Jan 2005 | A1 |
| 20050027207 | Westbrook et al. | Feb 2005 | A1 |
| 20050078533 | Vyshedskiy et al. | Apr 2005 | A1 |
| 20050124864 | Mack et al. | Jun 2005 | A1 |
| 20050234353 | Xue et al. | Oct 2005 | A1 |
| 20050239493 | Batkin et al. | Oct 2005 | A1 |
| 20060022833 | Ferguson et al. | Feb 2006 | A1 |
| 20060047215 | Newman et al. | Mar 2006 | A1 |
| 20060173259 | Flaherty et al. | Aug 2006 | A1 |
| 20060190045 | Marcus et al. | Aug 2006 | A1 |
| 20060193270 | Gehasie et al. | Aug 2006 | A1 |
| 20060252999 | Devaul et al. | Nov 2006 | A1 |
| 20070021677 | Markel | Jan 2007 | A1 |
| 20070027386 | Such et al. | Feb 2007 | A1 |
| 20070032731 | Lovejoy et al. | Feb 2007 | A1 |
| 20070063850 | Devaul et al. | Mar 2007 | A1 |
| 20070073266 | Chmiel et al. | Mar 2007 | A1 |
| 20070106179 | Bagha et al. | May 2007 | A1 |
| 20070156060 | Cervantes et al. | Jul 2007 | A1 |
| 20070167850 | Russell et al. | Jul 2007 | A1 |
| 20070254604 | Kim | Nov 2007 | A1 |
| 20070265038 | Kim | Nov 2007 | A1 |
| 20080009759 | Chetham et al. | Jan 2008 | A1 |
| 20080058670 | Mainini | Mar 2008 | A1 |
| 20080112885 | Okunev et al. | May 2008 | A1 |
| 20080146890 | Leboeuf et al. | Jun 2008 | A1 |
| 20080146892 | Leboeuf et al. | Jun 2008 | A1 |
| 20080171945 | Dotter | Jul 2008 | A1 |
| 20080177162 | Bae et al. | Jul 2008 | A1 |
| 20080198872 | Pierce | Aug 2008 | A1 |
| 20080214903 | Orbach | Sep 2008 | A1 |
| 20080228045 | Gao et al. | Sep 2008 | A1 |
| 20080293453 | Atlas et al. | Nov 2008 | A1 |
| 20080300641 | Brunekreeft et al. | Dec 2008 | A1 |
| 20090010461 | Klinghult et al. | Jan 2009 | A1 |
| 20090024045 | Prakash et al. | Jan 2009 | A1 |
| 20090037575 | Crystal et al. | Feb 2009 | A1 |
| 20090069642 | Gao et al. | Mar 2009 | A1 |
| 20090117883 | Coffing et al. | May 2009 | A1 |
| 20090144080 | Gray et al. | Jun 2009 | A1 |
| 20090149767 | Rossetti | Jun 2009 | A1 |
| 20090156908 | Belalcazar et al. | Jun 2009 | A1 |
| 20090171170 | Li et al. | Jul 2009 | A1 |
| 20090209873 | Pinter et al. | Aug 2009 | A1 |
| 20090273467 | Elixmann et al. | Nov 2009 | A1 |
| 20090279389 | Irie | Nov 2009 | A1 |
| 20090287067 | Dorogusker et al. | Nov 2009 | A1 |
| 20090306485 | Bell | Dec 2009 | A1 |
| 20090312655 | Lo | Dec 2009 | A1 |
| 20100027379 | Saulnier et al. | Feb 2010 | A1 |
| 20100033303 | Dugan et al. | Feb 2010 | A1 |
| 20100035927 | Ojika et al. | Feb 2010 | A1 |
| 20100042008 | Amitai et al. | Feb 2010 | A1 |
| 20100049006 | Magar et al. | Feb 2010 | A1 |
| 20100049037 | Pinter et al. | Feb 2010 | A1 |
| 20100063381 | Greiser | Mar 2010 | A1 |
| 20100069735 | Berkner | Mar 2010 | A1 |
| 20100076276 | Gilland | Mar 2010 | A1 |
| 20100076331 | Chan et al. | Mar 2010 | A1 |
| 20100094152 | Semmlow | Apr 2010 | A1 |
| 20100113950 | Lin et al. | May 2010 | A1 |
| 20100148956 | Song et al. | Jun 2010 | A1 |
| 20100184479 | Griffin, Jr. | Jul 2010 | A1 |
| 20100185101 | Sakai et al. | Jul 2010 | A1 |
| 20100204758 | Boon et al. | Aug 2010 | A1 |
| 20100208434 | Kim et al. | Aug 2010 | A1 |
| 20100217099 | Leboeuf et al. | Aug 2010 | A1 |
| 20100217100 | Leboeuf et al. | Aug 2010 | A1 |
| 20100217345 | Wolfe et al. | Aug 2010 | A1 |
| 20100234746 | Sebelius et al. | Sep 2010 | A1 |
| 20100256509 | Kuo et al. | Oct 2010 | A1 |
| 20100256976 | Atsmon et al. | Oct 2010 | A1 |
| 20100281261 | Razzell | Nov 2010 | A1 |
| 20100298711 | Pedersen et al. | Nov 2010 | A1 |
| 20100324378 | Tran et al. | Dec 2010 | A1 |
| 20100331631 | MacLaughlin | Dec 2010 | A1 |
| 20110015496 | Sherman et al. | Jan 2011 | A1 |
| 20110035927 | Griffin et al. | Feb 2011 | A1 |
| 20110060251 | Verma et al. | Mar 2011 | A1 |
| 20110066042 | Pandia et al. | Mar 2011 | A1 |
| 20110117529 | Barash et al. | May 2011 | A1 |
| 20110134725 | Su et al. | Jun 2011 | A1 |
| 20110160601 | Wang et al. | Jun 2011 | A1 |
| 20110182445 | Atsmon et al. | Jul 2011 | A1 |
| 20110208076 | Fong et al. | Aug 2011 | A1 |
| 20110235466 | Booij et al. | Sep 2011 | A1 |
| 20110275950 | Xue et al. | Nov 2011 | A1 |
| 20110288425 | Stewart | Nov 2011 | A1 |
| 20110301435 | Albert et al. | Dec 2011 | A1 |
| 20110301439 | Albert et al. | Dec 2011 | A1 |
| 20120051187 | Paulson et al. | Mar 2012 | A1 |
| 20120053424 | Kenalty et al. | Mar 2012 | A1 |
| 20120071734 | Shimuta et al. | Mar 2012 | A1 |
| 20120083705 | Yuen et al. | Apr 2012 | A1 |
| 20120101396 | Solosko et al. | Apr 2012 | A1 |
| 20120108916 | Riftine | May 2012 | A1 |
| 20120123891 | Patel | May 2012 | A1 |
| 20120127833 | Ghen et al. | May 2012 | A1 |
| 20120143018 | Skidmore et al. | Jun 2012 | A1 |
| 20120147921 | Conti et al. | Jun 2012 | A1 |
| 20120157019 | Li | Jun 2012 | A1 |
| 20120158090 | Chavan et al. | Jun 2012 | A1 |
| 20120171963 | Tsfaty | Jul 2012 | A1 |
| 20120172689 | Albert et al. | Jul 2012 | A1 |
| 20120179056 | Moulder et al. | Jul 2012 | A1 |
| 20120197148 | Levitan | Aug 2012 | A1 |
| 20120285588 | Sheppard | Nov 2012 | A1 |
| 20120289790 | Jain et al. | Nov 2012 | A1 |
| 20120316413 | Liu et al. | Dec 2012 | A1 |
| 20130003852 | Yamamoto | Jan 2013 | A1 |
| 20130030259 | Thomsen et al. | Jan 2013 | A1 |
| 20130085364 | Lu et al. | Apr 2013 | A1 |
| 20130122810 | Kaufman | May 2013 | A1 |
| 20130156194 | Tanioka | Jun 2013 | A1 |
| 20130159699 | Torkkel | Jun 2013 | A1 |
| 20130197320 | Albert et al. | Aug 2013 | A1 |
| 20130236980 | Moretti et al. | Sep 2013 | A1 |
| 20130261414 | Tal et al. | Oct 2013 | A1 |
| 20130281816 | Strauss et al. | Oct 2013 | A1 |
| 20130289366 | Chua et al. | Oct 2013 | A1 |
| 20130331663 | Albert et al. | Dec 2013 | A1 |
| 20140050321 | Albert et al. | Feb 2014 | A1 |
| 20140051941 | Messerschmidt | Feb 2014 | A1 |
| 20140051946 | Arne et al. | Feb 2014 | A1 |
| 20140066798 | Albert | Mar 2014 | A1 |
| 20140073486 | Ahmed et al. | Mar 2014 | A1 |
| 20140073969 | Zou et al. | Mar 2014 | A1 |
| 20140094707 | Farringdon et al. | Apr 2014 | A1 |
| 20140114166 | Baxi | Apr 2014 | A1 |
| 20140163927 | Molettiere et al. | Jun 2014 | A1 |
| 20140221859 | Albert | Aug 2014 | A1 |
| 20140276162 | Albert et al. | Sep 2014 | A1 |
| 20150018660 | Thomson et al. | Jan 2015 | A1 |
| 20150073285 | Albert et al. | Mar 2015 | A1 |
| 20150087952 | David et al. | Mar 2015 | A1 |
| 20150182132 | Harris et al. | Jul 2015 | A1 |
| 20150265164 | Gopalakrishnan et al. | Sep 2015 | A1 |
| 20150297134 | Albert et al. | Oct 2015 | A1 |
| 20160071392 | Hankey et al. | Mar 2016 | A1 |
| 20160235319 | Albert | Aug 2016 | A1 |
| 20160331247 | Albert | Nov 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 675675 | Oct 1990 | CH |
| 1798522 | Jul 2006 | CN |
| 101152081 | Apr 2008 | CN |
| 101828915 | Sep 2010 | CN |
| 102138789 | Aug 2011 | CN |
| 201918016 | Aug 2011 | CN |
| 102347804 | Feb 2012 | CN |
| 105338892 | Feb 2016 | CN |
| 2506936 | Sep 1976 | DE |
| 4212670 | Jan 1994 | DE |
| 0631226 | Dec 1994 | EP |
| 1181888 | Sep 2007 | EP |
| 1238633 | Oct 2008 | EP |
| 2030565 | Mar 2009 | EP |
| 2192526 | Jun 2010 | EP |
| 2116183 | Feb 2012 | EP |
| 2986204 | Feb 2016 | EP |
| 3079571 | Oct 2016 | EP |
| 3133984 | Mar 2017 | EP |
| 2740426 | Apr 1997 | FR |
| 2181554 | Apr 1987 | GB |
| 2408105 | May 2005 | GB |
| S59122032 | Jul 1984 | JP |
| S59190742 | Oct 1984 | JP |
| S63072231 | Apr 1988 | JP |
| S63294044 | Nov 1988 | JP |
| H01244328 | Sep 1989 | JP |
| H05167540 | Jul 1993 | JP |
| H06326669 | Nov 1994 | JP |
| 2002191562 | Jul 2002 | JP |
| 2002261731 | Sep 2002 | JP |
| 2003010177 | Jan 2003 | JP |
| 2005295378 | Oct 2005 | JP |
| 2006180899 | Jul 2006 | JP |
| 2008532587 | Aug 2008 | JP |
| 2010166961 | Aug 2010 | JP |
| 2012065073 | Mar 2012 | JP |
| 20100059198 | Jun 2010 | KR |
| 2009011781 | May 2011 | MX |
| WO-8200910 | Mar 1982 | WO |
| WO-8805282 | Jul 1988 | WO |
| WO-9008361 | Jul 1990 | WO |
| WO-9206551 | Apr 1992 | WO |
| WO-9731437 | Aug 1997 | WO |
| WO-9838611 | Sep 1998 | WO |
| WO-9944494 | Sep 1999 | WO |
| WO-0041620 | Jul 2000 | WO |
| WO-0147597 | Jul 2001 | WO |
| WO-0157619 | Aug 2001 | WO |
| WO-02080762 | Oct 2002 | WO |
| WO-03075118 | Sep 2003 | WO |
| WO-03094720 | Nov 2003 | WO |
| WO-2004037080 | May 2004 | WO |
| WO-2006001005 | Jan 2006 | WO |
| WO-2006021956 | Mar 2006 | WO |
| WO-2006090371 | Aug 2006 | WO |
| WO-2007014545 | Feb 2007 | WO |
| WO-2007088315 | Aug 2007 | WO |
| WO-2008005015 | Jan 2008 | WO |
| WO-2008066682 | Jun 2008 | WO |
| WO-2009112976 | Sep 2009 | WO |
| WO-2010025166 | Mar 2010 | WO |
| WO-2010099066 | Sep 2010 | WO |
| WO-2010108287 | Sep 2010 | WO |
| WO-2010113354 | Oct 2010 | WO |
| WO-2010144626 | Dec 2010 | WO |
| WO-2011006356 | Jan 2011 | WO |
| WO-2011008838 | Jan 2011 | WO |
| WO-2011014292 | Feb 2011 | WO |
| WO-2011022942 | Mar 2011 | WO |
| WO-2011040877 | Apr 2011 | WO |
| WO-2011040878 | Apr 2011 | WO |
| WO-2011113070 | Sep 2011 | WO |
| WO-2011137375 | Nov 2011 | WO |
| WO-2011156374 | Dec 2011 | WO |
| WO-2012046158 | Apr 2012 | WO |
| WO-2012108895 | Aug 2012 | WO |
| 2012125135 | Sep 2012 | WO |
| WO-2012129413 | Sep 2012 | WO |
| WO-2012160550 | Nov 2012 | WO |
| WO-2013028960 | Feb 2013 | WO |
| WO-2013036307 | Mar 2013 | WO |
| WO-2013066642 | May 2013 | WO |
| WO-2013093690 | Jun 2013 | WO |
| WO-2013122788 | Aug 2013 | WO |
| WO-2013138500 | Sep 2013 | WO |
| WO-2013155196 | Oct 2013 | WO |
| WO-2013192166 | Dec 2013 | WO |
| WO-2014172451 | Oct 2014 | WO |
| WO-2016183515 | Nov 2016 | WO |
| Entry |
|---|
| Adidas miCoach Pacer Review: Like Nike+, Only Better; printed from website http://gizmodo.com/5479456/adidas⋅ printed on Mar. 4, 2010. 5 pages. |
| Australian Design Awards. Heartplus Micro; printed from website http://www.designawards.com/au; printed on Apr. 12, 2002 ⋅ 6 pages. |
| Bajaj, M.D.; “Event Recording in Ambulatory Patients with Syncopal Events”; University of Kansas; Wichita, Kansas; (no date); pp. 15-18; printed on or before Apr. 14, 2010. |
| Bluetooth. Headset Profile (HSP), printed from website http://bluetooth.com/English/Techmology/Works/Pates/HSP.asgx, printed on May 12, 2010, 1 page. |
| Bramanti et al., Multichannel telemetric system for biomedical signals via switched telephone lines, Medical and Biological Engineering and Computing, Sep. 1982, vol. 20, No. 5, pp. 653-656. |
| Burke, “A Micropower Dry-Electrode ECG Preamplifier”, IEEE Transactions on Biomedical Engineering, Feb. 2000, vol. 47, No. 2, pp. 155-162. |
| Card Guard CG-6108 Act Ambulatory Cardiac Telemetry Brochure; Card Guard; The Telemedicine Company: Switzerland; 2006; 2 pages. |
| Cardiocomm Solutions; Gems Air. (PC based ECG management) printed from website http://www.cardiocommsolutions/com; printed on Mar. 19, 2010; 1 page. |
| Carpenter and Frontera, Smart-watches: a potential challenger to the implantable loop recorder? Europace, 18:791-793, 2016. |
| Charuvastra. Transtelephonic Cardiac Event Recording for Arrhythmia Surveillance; printed from website http://tchin.org/resource room/c art⋅ printed on Mar. 26, 2010⋅ 2 pages. |
| Cheng, Allen C.; “Real-Time Cardiovascular Diseases Detection on a Smartphone”; Departments of Electrical and Computer Engineering, Bioengineering, Neurological Surgery and Computer Science; University of Pittsburgh; Pittsburgh, PA; printed on or before Apr. 14, 2010, 2 pages. |
| Chinese Patent Application No. 2013800135500 First Office Action dated Oct. 20, 2015. |
| Creative. PC-80B Portable ECG Monitor w/sd card extension slot; printed from website www.amazon.com/Portable-Monitor-extension-leather-shipping/dp/B0010jWKUE; printed on Feb. 4, 2010⋅ 5 pages. |
| Deveau, “Health Care eyes smart phones to heal ills”, printed from the website http://www.theQiobeandmail.com on Sep. 17, 2009, 4 pages. |
| Dinh. Heart activity monitoring on smartphone. IPCBEE-Int. Conf. Biomedical Eng and Technol. Jun. 17-19, 2011. 11:45-49. |
| Dobrev, et al., Bootstrapped two-electrode biosignal amplifier, Med Bioi Eng Comput, 2008, 7 pages. |
| Dolan; Qualcomm launches ECG smartphone program in China; Sep. 8, 2011; 11 pgs.; retrieved Mar. 19, 2011; from the internet (http://mobihealthnews.com/13092/qualcomm-launches-ecg-smartphone-program-in-china/). |
| Elert, Glenn (Editor); Frequency Range of Human Hearing; The Physics Factbook; web version as of Mar. 29, 2010; 2 pgs.; printed Jun. 6, 2012 (http://web.archive.org/web/20100329141847/http:I/hypertextbook.com/facts/2003/ChrisDAmbrose.shtml). |
| European Patent Application No. 14785223.0 extended European Search Report dated Aug. 23, 2016. |
| European Search Report and opinion dated Nov. 21, 2014 for EP Application No. 11865699.0. |
| Favorite Plus. Handheld Easy ECG Monitor—Handheld Easy EKG Monitor; printed from website www.favoriteplus.com/easy-ecg-handgeld-monitor-fp; printed on Feb. 4, 2010; 2 pages. |
| Favorite Plus. Handheld ECG Monitor—Handheld EKG Monitor at Favoriteplus.com; printed from website www.favoriteplus.com/handheld-ecg-ekg-monitor; printed on Feb. 4, 2010; 3 pages. |
| Favorite Plus. Handheld ECG Monitor—Handheld EKG Monitor InstantCheck; printed from website http://www. favoriteplus.com/instanchcheck-hand held-ecg-ekg-monitor; printed on Feb. 4, 2010; 2 pages. |
| Ferrick, M.D.; “Holter Monitoring and cardiac Event Recording in Assessing Symptomatic Patients”; Albert Einstein College of Medicine; Bronx, New York; (no date)⋅ pp. 11-14⋅ printed on or before Apr. 14, 2010. |
| FREE2MOVE. Vitaphone 2300; www.free2move.us/News/NewsVitaghone 240105.htm printed May 12, 2010. |
| Fulford-Jones, et al., “A Portable, Low-Power, Wireless Two-Lead EKG System”, Division of Engineering and Applied Sciences, Harvard University, Sep. 2004, 4 pages. |
| Garabelli et al. Accuracy and Novelty of an Inexpensive iPhone-based Event Recorder (Presentation Poster/Abstract) Heart Rhythm 2012, 33rd Annual Scientific Session. SP23. Innovation Poster Session II. No. IA02-1; May 11, 2012. |
| GBI Portal. Qualcomm's wireless reach mHealth project to improve cardiovascular disease in resource scarce China; Feb. 17, 2012; 7 pgs. Retrieved Mar. 19, 2014 from www.intergrallc.com/2012/02/17/qualcooms-wireless-reach-mhealth-project-to-improve-cardiovascular-disease-in-resource-scarce-china/. |
| GE; Healthcare., “Marquette heart rate turbulence analysis program”, 2005, DC-0160-12.05-EN-US. 4 pages. |
| Gillette, M.D.; “Diagnosis of Pediatric Arrhythmias with Event Recording”; Medical University of South Carolina; Charleston, South Carolina; (no date); pp. 25-32; printed on or before Apr. 14, 2010. |
| Grier, James W.; “How to use 1-lead ECG recorders to obtain 12-lead resting ECGs and exercise (“stress”) ECGs”; Department of Biological Sciences: printed from website http://www.ndsu.edu/pubweb/rvgrier; printed on Jun. 7, 2010; 13 pages. |
| Hannaford, Kat; “How to Turn Your iPhone Into a Laser, Fan or Flashlight”; printed from website http://m.qizmodo.com/5534904⋅ printed on Feb. 3, 2011, 2 pages. |
| Hartmann, “ECG Front-End Design is Simplified with MicroConverter” Analog Dialogue, Nov. 2003, vol. 37, pp. 1-5. |
| Hayes, M.D.; “Approaches to Diagnosing Transient Arhythmias” An Overview; Mayo Clinic; Rochester Minnesota; (no date); pp. 7-10; printed on or before Apr. 14, 2010. |
| Hearing Loss Assoc. of Kentuckiana; Decibel Ratings/Hazardous Time Exposures of Common Noise (excerpt from Survivor's Manual); web version as of Oct. 5, 2008; 2 pgs.; printed Jun. 6, 2012 (http://web.archive.org/web/20081005143856/http://www.hearinglossky.orglhlasurvival1.html). |
| Huang, Tina; Age-related hearing loss; Minnesota Medicine; 90(10); pp. 48-50; Oct. 2007; printed Jun. 6, 2012 from: http://www.minnesotamedicine.com/PastIssues/PastIssues2007/October2007/Ciinca1Huang0ctober2007.aspx). |
| IMEC News; IMEC extends flexible ECG patch to enable arrhythmia detection; printed from website http://www2.imec.be/imeC' printed on Aug. 18, 2009 1 page. |
| Instromedix. Cardiac Event Recording FAQ's; Instromedix a Card Guard Company, San Diego, CA.; printed from website www.instromedix.com/pdf/products/cardiac; printed on or before Apr. 14, 2010. |
| Instromedix. The Arrhythmia Monitoring System; King of Hearts Express AF Recorder Brochure from Instromedix⋅ A CardGuard Company; Rosemont IL; 2004. 3 pages. |
| International preliminary report on patentability dated Jul. 29, 2014 for PCT/US2013/023370. |
| International search report and written opinion dated Feb. 12, 2015 for PCT Application No. US2014/054414. |
| International search report and written opinion dated Feb. 17, 2012 for PCT/US2011/039445. |
| International search report and written opinion dated Apr. 27, 2012 for PCT/US2011/053708. |
| International search report and written opinion dated Apr. 30, 2015 for PCT/US2014/070170. |
| International search report and written opinion dated May 15, 2013 for PCT/US2013/023370. |
| International search report and written opinion dated Dec. 17, 2013 for PCT/US2013/055458. |
| International search report dated Sep. 1, 2014 for PCT/US2014/034350. |
| International search report dated Dec. 10, 2013 for PCT/US2013/057576. |
| Japanese Patent Application No. 2014-511335 Decision of Rejection dated Jul. 28, 2016. |
| Japanese Patent Application No. 2014-554916 Office Action dated Sep. 26, 2016. |
| Jenkins II, W.; Time/Frequency Relationships for an FFT-Based Acoustic Modem; Naval Postgraduate School; pp. 1-102; Sep. 2010 (http://edocs.nps.edu/npspubs/scholarly/theses/2010/Sep/1 OSep_Jenkins.pdf) printed Oct. 2, 2013. |
| Kim, et al., “Detection of Atrial Fibrillation Episodes using Multiple Heart Rate Variability Features in Different Time Periods.” Conference Proceedings IEEE Eng Med Biol Soc EMBS, 30th Annual International Conference, Aug. 20-25, 2008, p. 5482-5485. |
| Koerner. The Author's Metrics; Wired Magazine Article; New York, NY; Jul. 2009; p. 93-126. |
| Kumar, M.D., “Zio Patch”, printed from website http://www.irhythmtech.com/zio-solution/zio-gach/, grinted on Apr. 12, 2010. |
| Kumparak, Greg; “Visa officially announces their case that turns your iPhone into a credit card (and we've got pies!)”; May 17, 2010; printed from website www.mobilecrunch.com⋅ printed on Feb. 3, 2011. |
| Lau, et al. iPhone ECG application for community screening to detect silent atrial fibrillation: A novel technology to prevent stroke. Int J Cardiol. Apr. 30, 2013;165(1):193-4. |
| Lau, et al. Performance of an Automated iPhone ECG Algorithm to Diagnose Atrial Fibrillation in a Community AF Screening Program (SEARCH-AF). Heart, Lung and Circulation. 2013; 22:S205. |
| Lau et al. Validation of an iPhone ECG application suitable for community screening for silent atrial fibrillation—A novel way to prevent stroke (Presentation Abstract 16810); American Heart Association 2012 Scientific Sessions and Resuscitation Science Symposium; 126(1); Nov. 20, 2012, 2 pages. |
| Leijdekkers et al., “Trial Results of a Novel Cardiac Rhythm Management System using Smart Phones and wireless ECG Sensors”, Proceedings of the International Conf. on Smart homes and health Telematics., Jul. 1-3, 2009, Tours, France, 8 pages. |
| Levkov et al., “Removal of power-line interference from the ECG: a review of the subtraction procedure” BioMedical Engineering Online 2005, printed from website httg://www.biomedical-engineeringonline.com/contenU4/1/50 pp. 1-18. |
| Lin; et al., “An intelligent telecardiology system using a wearable and wireless ECG to detect atrial fibrillation.”, May 2010, 14(3), 726-33. |
| Lowres, et al. Screening Education and Recognition in Community Pharmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged =65 years SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open. Jun. 25, 2012; 2(3)e001355. |
| M Med Choice. Handheld ECG Monitor Brochure; M Med Choice, Beijing Choice Electronic Technology Co. Ltd.⋅ published on or before Apr. 14, 2010, 6 pages. |
| M Med Choice. Handheld ECG Monitor MD100A1; printed from website http://www.choicemmed.com/productshow.as_p; printed on Dec. 28, 2009; 2 pages. |
| M Med Choice. Handheld ECG Monitor MD10013; printed from website: http://www.choicemmed.com/productshow.asp; printed on Dec. 28, 2009⋅ 2 pages. |
| M Med Choice printed from website: http://www.choicemmed.con/1xwm .asp; printed on Dec. 28, 2009⋅ 1 page. |
| MacFarlane, et al. Resting 12-lead ECG electrode placement and associated problems; SCST update 1995; 15pgs. Printed Feb. 18, 2014 from www.scst.org.uk/resources/RESTING_12.pdf. |
| Mauvila ECG Tutorial; Basic ECG Interpretation Tutorial; Sections 1-12; printed from website http://mauvila.com/ECG/ecg.htm⋅ printed on Mar. 26, 2010. 56 pages. |
| Medgadget. Zio Patch Wins Medical Design Award.MedGadget internet journal of emerging medical technologies, 2010, 1 page, printed from website: http://medaadaet.com/archives/2010/04/zio_patch_wins_medial_design_award_1.html. |
| MiCardioMobile: Remote Wireless Cardiac Rehabilitation Monitoring printed from website htto://alivetec.cable.nu/cardiomobile⋅ printed on or before Apr. 14, 2010, 1 page. |
| Mobility Mind. Use your Treo 650 as a portable ECG monitoring device, Mobility Mind Celebrating mobile Internet lifestyle and culture, Sep. 14, 2005, 1 page. printed from website httg://www.treotoday.net/2005/09/14/use-your-treo-650-as-a-portab le-ecg-monitoring-device/. |
| Modem Protocols Explained; ftp://kermit.columbia.edu/kermit/cu/protocol.html; 5 pgs.; printed Oct. 2, 2013. |
| Modem Tutorial; http://www.lsu.edu/OCS/its/unix/tutoriai/ModemTutoriai/ModemTutorial.html; 2 pgs.; printed Oct. 2, 2013. |
| Muench, Frederick, PhD; “HRV: The Manufacturers and Vendors Speak; The portable StressEraser Heart Rate Variability Biofeedback Device: Background and Research”. Biofeedback vol. 36 Issue 1, pp. 35-39⋅ published Spring 2008. |
| Murph. RedEye mini converts iPhone, iPad or iPod touch into IR-beaming universal remote; printed from website http://www.engadget.com/2010/03/02/redeye; printed on Mar. 2, 2010; 3 pages. |
| Nam et al.; An Ultrasonic Sensor Based Low-Power Acoustic Modem for Underwater Communication in Underwater Wireless Sensor Networks; Computer Network Lab, Dept. of Elec. Eng., Korea Univ.; pp. 494-504; Dec. 2007 (http://nesl.ee.ucla.edu/fw/torres/home/Dropbox/good_paper_mico_controller.pdf; 11 pgs.; printed Oct. 2, 2013). |
| Neuroreille; Audiometry; web version as of Oct. 14, 2008; 1 pg.; printed Jun. 6, 2012 (http://www.neuroreille.com/promenade/english/audiometry/audiometry.htm). |
| New Professional Quality ECGEKG Portable Heart Monitor; printed from website http://cgibay.com/ws/eBayiSAPI.d11⋅ printed on Feb. 4, 2010⋅ 3 pages. |
| Notice of allowance dated Jan. 8, 2014 for U.S. Appl. No. 14/015,303. |
| Notice of allowance dated Jan. 27, 2014 for U.S. Appl. No. 14/015,303. |
| Notice of allowance dated Feb. 26, 2014 for U.S. Appl. No. 14/015,303. |
| Notice of allowance dated May 23, 2014 for U.S. Appl. No. 13/108,738. |
| Notice of allowance dated Jul. 9, 2013 for U.S. Appl. No. 12/796,188. |
| Notice of allowance dated Aug. 28, 2012 for U.S. Appl. No. 13/420,520. |
| Notice of allowance dated Dec. 4, 2013 for U.S. Appl. No. 14/015,303. |
| Notice of Allowance dated Jun. 16, 2016 for U.S. Appl. No. 14/569,513. |
| Notice of Allowance dated Mar. 29, 2016 for U.S. Appl. No. 14/254,310. |
| Office action dated Jan. 2, 2014 for U.S. Appl. No. 13/108,738. |
| Office action dated Jun. 18, 2012 for U.S. Appl. No. 13/420,520. |
| Office action dated Sep. 12, 2014 for U.S. Appl. No. 13/108,738. |
| Office action dated Oct. 6, 2014 for U.S. Appl. No. 14/252,044. |
| Office action dated Oct. 29, 2012 for U.S. Appl. No. 12/796,188. |
| Office action dated Nov. 19, 2014 for U.S. Appl. No. 13/969,446. |
| Office Action dated Aug. 25, 2015 for U.S. Appl. No. 14/479,105. |
| Office Action dated Dec. 21, 2015 for U.S. Appl. No. 13/964,490. |
| Office Action dated Feb. 24, 2016 for U.S. Appl. No. 14/730,122. |
| Office Action dated Jun. 13, 2016 for U.S. Appl. No. 14/730,122. |
| Office Action dated May 18, 2015 for U.S. Appl. No. 13/752,048. |
| Office Action dated Oct. 6, 2015 for U.S. Appl. No. 14/569,513. |
| Omron Portable ECG EKG Handheld HCG-801 Monitor; printed from website http://www.amazon.com/Omron-Portable-Handheld-HCG-801-Monitor/dp/B0019WH3EO⋅ printed on Feb. 24, 2010⋅ 5 pages. |
| Omron Portable ECG Monitor; printed from website http://www.target.com/gp/detail.html; printed on Mar. 26, 2010⋅ 1 page. |
| Oresko, et al., “Detecting Cardiovascular Diseases via Real-Time Electrocardiogram Processing on a Smartphone”, 2009 Workshop on Biomedicine in Computing: Systems, Architectures, and Circuits, pp. 13-16. |
| PCT Patent Application No. PCT/US2014/070170 International Preliminary Report on Patentability dated Jun. 23, 2016. |
| PCT/US2014/054414 International Preliminary Report on Patentability dated Mar. 17, 2016. |
| PCT/US2016/032524 International Search Report and Written Opinion dated Aug. 19, 2016. |
| Perez, Sarah; No NFC? No Problem; New Startup Zoosh Provides Workaround Technology (Jun. 20, 2011 ); printed on or before Jun. 27, 2011 from website; 2 pgs.; (http://www.readwriteweb.com/archives). |
| Prystowsky, M.D.; “Chairman's Introduction”; Duke University Medical Center; Indianapolis, Indiana⋅ (no date)⋅ pp. 5-6⋅ printed on or before Apr. 14, 2010. |
| Prystowsky, M.D.; “Chairman's Summary”; Duke University Medical Center; Indianapolis Indiana; (no date); pp. 39-40⋅ printed on or before Apr. 14, 2010. |
| Prystowsky, M.D., “The Clinical Application, Diagnostic Yield and Cost Considerations of Cardiac Event Recorders”, Indianapolis, Indiana (no date) pp. 19-23. printed on or before Apr. 14, 2010. |
| Puurtinen, et al., Best Electrode Locations for a Small Bipolar ECG Device: Signal Strength Analysis of Clinical Data, Annals of Biomedical Engineering, vol. 37, No. 2, Feb. 2009 ( © ) 2008) pp. 331-336. |
| Raju Heart-Rate and EKG Monitor Using the MSP430FG439, SLAA280—Oct. 2005—Revised Sep. 2007, 11 pages. |
| Read-My-Heart. ECG Machine Handheld Read MyHeart; (product item No. HH-3413) printed from website http://www.helioliving.com/ECG-Machine-Handheld-ReadMyHeart; printed on Feb. 4, 2010; 1 page. |
| Read-My-Heart Personal Handheld ECG Monitor with Free Illustrator Book & Free Electrodes V2.2; printed from website http://www .amazon.com/Readmyheart-Personai-Handheld-illustrator-Eiectrodes/dp/B0010AN63W; printed on Mar. 26, 2010; 4 pages. |
| Ricker. Square payment dongle demoed for iPhone toting hippies and you (video); printed from website http://www.engadget.com/2010/01/18/square-payment; printed on Jan. 18, 2010; 6 pages. |
| Rockwood. The Networked Body Magazine Article from FAST TALK Magazine; Jul./Aug. 2009; pp. 19-26. |
| Salahuddin, et al., “Ultra Short Term Analysis of Heart Rate Variability using Normal Sinus Rhythm and Atrial Fibrillation ECG Data”, Engineering in Medicine and Biology Society, Aug. 2007, pp. 4656-4659. |
| Saxon, et al. iPhone rhythm strip—the implications of wireless and ubiquitous heart rate monitoring. JACC; 59(13): E726; Mar. 2012. |
| Saxon. Ubiquitous Wireless ECG Recording: A Powerful Tool Physicians Should Embrace. J Cardiovasc Electrophysiol. 24(4):480-483; Apr. 2013. |
| Semler, M.D.; “The Future of Cardiac Event Monitoring”; St. Vincent Hospital and Medical Center; Portland Oregon; (no date); pp. 33-37; printed on or before Apr. 14, 2010. |
| SFO Medical. Choice Portable Handheld ECG EKG Monitor; printed from website http://www.amazon.com/Choice-Portable-Handheld-ECG-Monitor/dp/B001Q74VOM; printed on Mar. 26, 2010; 1 page. |
| Shenzhen New Element Med. Equipment. Wireless ECG Monitoring System, printed from website http://www.alibaba.com/product-gs/248168581/Wireless_ECG_Monitoring_system.html., printed on Mar. 26, 2010, 2 pages. |
| Shumaker, J.; Designing an Ultrasonic Modem for Robotic Communications; Army Research Laboratory; 26 pgs.; Mar. 2009 (http://www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA499556) printed Oct. 2, 2013. |
| Smith. Smartphone may keep the cardiologist away, The Independent, Health & Families, Mar. 5, 2010, printed from website http://www.independent.co.uk/life-style/health-and-families/healthnews/smartghone-may-keep-the-cardiologist-away-1916652. html, printed on Mar. 26, 2010. |
| Stevens, “Apple's Seamlessly Embedded Heart Rate Monitor could turn the iPhone into a new-age mood ring”, printed from the website http://www.enaadaet.com on May 6, 2010, 3 pages. |
| Taleb Medical. Observer Hand-held ECG Monitor MD100B; (no date); printed on or before Apr. 14, 2010, 1 page. |
| Tei, et al., New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function—a study in normal and dilated cardiomyopathy; J Cardiol.; 26(6):357-366; Dec. 1995. |
| Texas Instruments. Information for Medical Applications, “Biophysical Monitoring—Electrocardiogram (ECG) Front End”, Apr. 2004, 2 pages. |
| Tschida. Power A's New Case Turns Your iPhone Into a Universal Remote; printed from website http://appadvice.com/appnn; printed on Mar. 1, 2010⋅ 2 pages. |
| U.S. Appl. No. 14/479,105 Office Action dated Jul. 22, 2016. |
| U.S. Appl. No. 14/494,191 Office Action dated Jul. 20, 2016. |
| U.S. Appl. No. 14/730,122 Notice of Allowance dated Dec. 6, 2016. |
| Vanhemert, Kyle; “XWave Headset Lets You Control iPhone Apps With Your BRAIN”; Sep. 8, 2010; printed from website http://gizmodo.com; printed on Sep. 8, 2010, 4 pages. |
| Vitaphone. Telemedicine since 1999: Modern health management is our special subject. 3 pgs. Retrieved Mar. 19, 2014 from www.vitaphone.de/en/company/history-of-vitaphone/. |
| Wikimedia Laboratories; Acoustics; web archive version dated Jan. 25, 2009; 2 pgs.; printed Jun. 6, 2012 (http://liveweb.archive.org/http://en.labs.wikimedia.org/wiki/Acoustics). |
| Wikipedia; Aliasing; web version as of Apr. 3, 2011; S pgs.; printed Jun. 6, 2012 (http://liveweb.archive.org/http://en.wikipedia.org/w/index.php?title=Aiiasing&oldid=422141882). |
| Wikipedia; Hearing Range; web version as of Feb. 6, 2010; 5 pgs.; printed Jun. 6, 2012 (http://web.archive.org/web/201 002062137 41/http://en.wikipedia.org/wiki/Hearing_range). |
| Wikipedia.“Pulse oximetry”, printed from website httg://en.wikigedia.orq on May 10, 2010, 4 pages. |
| Wisneski, C.; Ultrasonic Local Area Communication; http://alumni.media.mit.edu/-wiz/ultracom.html; 2 pgs.; printed Oct. 2, 2013. |
| Woodward et al; “Bio-Potentiai-To-Frequency Converter/Modulator”; Electronic Design⋅ Aug. 1999⋅ p. 117. |
| Ziegler, Chris; “EPI Life phone sports ECG function, can let doctors know if you're gonna make it”; printed from website www.enoadoet.com/2010/06/; Jun. 17 2010, 3 pages. |
| U.S. Appl. No. 15/140,072 Office Action dated Dec. 23, 2016. |
| European Patent Application No. 11793020.6 extended European Search Report dated Jan. 10, 2017. |
| European Patent Application No. 11865699.0 Communication dated Dec. 19, 2016. |
| U.S. Appl. No. 13/964,490 Notice of Allowance dated Jan. 6, 2017. |
| Chinese Patent Application No. 2014800331017 Office Action dated May 16, 2017. |
| European Patent Application No. 14869033.2 extended European Search Report dated Jul. 5, 2017. |
| U.S. Appl. No. 14/692,563 Office Action dated Jun. 29, 2017. |
| U.S. Appl. No. 15/154,849 Office Action dated Feb. 17, 2017. |
| Number | Date | Country | |
|---|---|---|---|
| 20170238814 A1 | Aug 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61915113 | Dec 2013 | US | |
| 61953616 | Mar 2014 | US | |
| 61969019 | Mar 2014 | US | |
| 61970551 | Mar 2014 | US | |
| 62014516 | Jun 2014 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14730122 | Jun 2015 | US |
| Child | 15393077 | US | |
| Parent | 14569513 | Dec 2014 | US |
| Child | 14730122 | US |
